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11 Introduction
1. Introduction
In this chapter we present the background information for the topics of this thesis.
First some general aspects of growth and growth modeling are discussed, to help
the reader understand the context of what we are doing. We then explain some
of the statistical techniques that we use. Finally an outline of this thesis is given.
1.1 General introduction
This thesis deals with models for growth. This, of course, is a rather generic term
and therefore we will explain exactly what is meant by growth models and how
the various chapters in this thesis are located within this field.
The term ‘growth model’ can mean both some kind of model that attempts to
describe (human) growth but also more generally a set of statistical models that
look at both within-individual and between individual patterns of change [Curran
et al., 2010; Grimm et al., 2016]. In this thesis we mostly study human physical
growth.
Human growth
First, when we talk about growth, we mean human growth. In human growth
studies we study various anthropological measurements and their development
over time. Growth is most pronounced in the period before birth where a single
cell (called zygote) is transformed into a baby of 3 to 3.5 kilos in a period of
approximately forty weeks. In this period the ‘gestational age’ is used to measure
the duration of the pregnancy. To determine the gestational age we start counting
from the last day of the last menstrual cycle, as the exact day of conception
is usually unknown. As the last day of the last cycle is often not known, the
gestational age is usually derived from the first ultrasound scan using reference
charts for the crown rump length. This prenatal growth can be subdivided in
the embryonic stage, which lasts until the tenth week of gestation, in which the
major structures are formed, and the fetal period in which the organs continue
to develop. In the postnatal period we distinguish between infancy, childhood
and puberty. Immediately after birth, growth is still quite fast but then rapidly
decreases until the age of 3. During childhood, the growth rate decreases further,
albeit much slower, until there is a growth spurt at puberty triggered by sex
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hormones. Thereafter growth decreases again until the adult height is reached.
This occurs, on average, at the age of 15 for girls and 17 for boys.
The field of research on human growth is large and diverse [Johnson, 2015]
and has a long history [Voss, 2001]. This interest mostly stems from the fact that
a ‘normal’ growth pattern is seen as a measure of health while abnormal growth
can be an indication of a disease. Various subtopics can be distinguished in this
field: Sometimes we simply want to describe the natural variation and patterns of
humangrowth. Wemaywish tomake predictions for individual growth outcomes
based on earlier observations. Sometimes we want to study what factors influence
growth. Finally, we can ask how growth impacts other outcomes later in life.
For example, there is evidence that intrauterine growth restriction can cause a
multitude of problems at adult ages. This is called the ‘fetal origin hypothesis’
[Barker, 1998].
Growth models in general
While we focused on human physical growth, research on growth occurs in many
areas: growths of plants, growth of an economy, etc. Many of the challenges we
have seen in the analysis of human growth data are also encountered in other
application fields where we also want to compare measurements with a reference
or where we also have repeated measurements of some kind. Sometimes the term
growth model is even used for any model that deals with any score that changes
over time and the growth curve model refers to statistical technique (a generalized
MANOVA) to model these data [Potthoff and Roy, 1964]. In this thesis we also will
show an application of a model originally developed for human growth applied
on the concentration of a drug in the bloodstream.
1.2 Statistical methods for growth studies
Regression models for growth
Modeling human growth has a long history. Some studies have been based
on cross-sectional measurements from individuals with various ages but most
research focuses on the growth of a specific individual repeatedly observed in
time [Scammon, 1927]. Various authors have looked for the most appropriate
3
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mathematical functions that fit the observed measurements best. This resulted,
for example, in the Jenss model [Jenss and Bayley, 1937], often used for height
and weight in children. Most of these models are rather complex and highly
nonlinear in their parameters. In the past these growth models were fitted for
each individual child separately. The subject-specific parameters obtained were
summarized further, e.g.: by calculating the average and standard deviation.
Splines
Some growth models, as discussed above, are highly non-linear and may be
difficult to fit to data. It may therefore be useful to look for alternative models
that are flexible enough to accommodate the non-linear patterns in the data. One
option is tomake use of (B-)splines [De Boor, 2001]. They are piecewise polynomial
functions of low order that are joined together in such away that they look smooth.
The positions where the pieces come together are called knots. Often restrictions
are placed on a spline function so that it is linear at the edge of its support. In this
case it is called a restricted or natural spline. Because splines are meant to be very
flexible there is a danger of over-fitting, especially when the number of knots is
large. This can be remedied by placing penalties on the spline coefficients. The
result is called a P-spline [Eilers and Marx, 1996].
Mixed models
Fitting a model for each individual combined with calculating summary statistics,
as described above, is not entirely satisfactory. For example, this approach is not
optimal when the study is plagued with missing data. A much better method is
formed by mixed effects models [Laird and Ware, 1982]. In these types of models
we simultaneously model the general pattern of development (formed by the
fixed effects) and the way the individuals deviate from this general pattern (which
is described by the random effects). In the simplest case the model is linear in
all parameters leading to linear mixed effects models. However often nonlinear
models are needed then resulting in nonlinear mixed effects models.
A specific type of nonlinear mixed effects model is the SITAR model [Cole
et al., 2010b], which will feature prominently in several of the following chapters.
This uses a template longitudinal pattern which is described by a spline function.
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Figure 1.1: Schematic representation of SITAR model with horizontal shift (γi1), vertical
shift (γi2) and stretch (γi3)
The individual growth profiles are then derived from this template by shifting the
curve along the horizontal and vertical axis and by stretching it (see Figure 1.1).
1.3 Multivariate models
Growth is intrinsically multivariate. We mean that a single dimension does
not give the total pictue of growth but the proportionality between them has to
be considered. The standard approach to growth modeling is however to look
at one outcome at a time. This may not always be optimal. For example,an
unusual observation might appear normal when examined univariately on its
own, but might still be outlying when looked at the total picture [Gnanadesikan
and Kettenring, 1972]. It is only when we look at the relations between the different
outcomes when this becomes apparent. Therefore, we argue that growth should
be considered as a multivariate process. Most existing techniques can only handle
a single response so here methodological development is needed.
Quantiles, expectiles and standard deviation scores
The methods above focus on the expected value of some random variable. We
might also be interested in the extremes of a distribution. We then ask the question
5
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how far away an observation is from the center and the range of values that can
still be considered to be within the normal range.
The most familiar example to most people, or at least most parents, are the
growth charts for height and weight which are used to check if young children
develop normally. Similar growth charts are also used for embryos, for example
to a predict the gestational age based on its size. Here often quantiles are used.
A quantile says what fraction of observations in the population are expected to
be lower. Quantiles expressed as a percentage are called percentiles or centiles.
An other generalization that is often used, is formed by standard deviation scores
(sds-scores) telling us howmany standard deviations ameasurement is away from
its mean.
One method to compute such quantities is by assuming some parametric
distribution. We can then estimate its parameters and derive the quantiles from
there. There are however also non-parametric methods that allow for direct
computation without the assumption of a specific parametric form.
To reduce the variation and make a comparison with respect to a meaningful
peer-group, quantiles are usually conditioned on age and often on sex. In practice,
in a data set the children do not have exactly the same age and we need some
modeling to estimate the relation between the ages and the quantiles. Often
quantile regression is used for this [Koenker, 2005]. This method minimizes the
weighed absolute residuals, usually with some linear programming technique.
There are alternatives to this non-parametric technique that are used to estimate
quantiles based on the whole distribution. In the LMS method [Cole, 1990] its is
assumed that the distribution can be transformed to a normal one after a Box-
Cox transformation. Now the parameters of this transformation as well as the
mean and the coefficient of variation of the resulting normal distribution are
modeled by means of a spline function of age; this results in the so called L
(transformation), M (location) and S (scale) curves fromwhich the method derives
its name. The generalized additive models for location scale and shape (gamlss)
are a generalization of the LMS method that allow us to use many more families
of distributions.
Expectiles constitute an interesting alternative to quantiles [Newey and Powell,
1987]. They generalize of the mean in the same way that the quantiles generalize
the median. The loss is now based on weighted squared residuals instead of
weighed absolute residuals. Expectile regression is carried out using the least
6
1.4. The Bayesian approach
asymmetrically weighed squares algorithm (LAWS). They are much easier to
compute than quantiles as least squares techniques can be used.
1.4 The Bayesian approach
The Bayesian approach is the basis for severalmodeling techniques in this thesis. It
combines prior believeswith the observeddata resulting in a posterior distribution.
Such a posterior represents our believes after having observed all evidence.
If we want to estimate the parameters in a model we need to be able to find
the posterior. A closed-form solution only exists in some special cases for very
basic models. Usually a numerical procedure has to be followed to sample from
the posterior. Often this is done using Markov Chain Monte Carlo (MCMC)
techniques [Gelfand and Smith, 1990]. This is a class of models in which the
posterior is approached by a sample on which further inference may be based.
The sample is drawn iteratively with each value depending on the previous one.
As the sample gets larger the approximation to the posterior gets better. Because,
unlike the sample of individuals, the sample from the posterior can theoretically
be made arbitrarily large when given enough time, one can in principle obtain
any precision deemed necessary. In complex models the type of MCMC-method
is often the Metropolis-Hastings algorithm or Gibbs sampling [Geman and Geman,
1984]. In each iteration of the Metropolis-Hastings algorithm we draw a sample
from some proposal distribution; we then either accept or reject this value with
some probability that is based on the ratio between the value of the distribution
in the proposed point and the value from the previous iteration [Hastings, 1970].
When the proposal is rejected we continue to use the previously accepted value.
The idea behind Gibbs sampling is that, given same starting values, we can sample
from a multivariate distribution by sampling from each of the parameters in turn
conditioning on all others (the full conditionals). Eventually the distribution
of the sample should converge to the target distribution which is the posterior.
There are various software packages that have implemented Gibbs sampling, e.g.:
WinBUGS, OpenBUGS and JAGS. The usefulness of Gibbs sampling is based on
the fact that generally it is much easier to sample from the full conditionals than
it is to sample from the posterior directly. For the full conditionals, often there is
even a closed form solutionwhen so called conditional conjugate priors are chosen.
When this is not the case other sampling techniques such as Metropolis-Hastings
7
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or a slice sampler can be used. In the slice sampler we first sample a value of the
distribution y which is below f (x′) where x′ is the current value of x. In the next
step we uniformly sample a new value of x from all values of for which f (x) is at
least equal to y [Neal, 2003]. When we useMCMCwewill (given some conditions)
eventually sample from the posterior but it is not clear how long this will take.
Furthermore the sample obtained from an MCMCmethod is generally correlated.
This makes it important to check convergence and asses the effective size of the
posterior sample.
1.5 Model evaluation
A simpleway to look atmodel performance is to evaluate the discrepancy between
the observed and predicted values. The Root Mean Squared Error (RMSE), which
is the standard error of the residuals can be used to this end. However the RMSE
is optimistic because models with a lot of parameters always perform better on the
estimation sample than on newdata. This optimistic behavior can be compensated
for by cross-validation: in this technique the data is split into subsets and the
residuals of the observations in each subset are based on a model developed on
the other subsets. These residuals are then used to calculate the cross-validated
RMSE. Because cross-validation involves fitting several models, it is computer
intensive.
An other way to evaluate models is using Akaike Information Criterion (AIC).
Its is defined as −2 log( f (y |θˆ)) + 2k where y are the observations and θˆ the
maximum likelihood estimator of the parameters vector θ, f (.) the likelihood
function of the model considered and k the effective degrees of freedom. In
simple models this is equal to the number of parameters. Expressed in words this
criterion penalizes the fit of themodel (asmeasured by the log likelihood function)
by the model complexity (expressed by the number of parameters). In a Bayesian
hierarchical model the number of parameters is not so easy to determine. The
Deviance Information Criterion (DIC) was proposed as a substitute for the AIC
in a Bayesian setting. The DIC is defined as D¯ + pD with pD given by D¯ − D(θ¯)
where the deviance D is defined as −2 log( f (y |θ)), D¯ is the average deviance in
the posterior samples and D(θ¯) is the deviance calculated at the posterior mode.
The effective number of parameters pD can be seen as ameasure of the flexibility of
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the model. The DICmay also be expressed asD(θ¯)+2pD making the resemblance
with the AIC more clear.
1.6 Outline of this thesis
In this section we introduce the different chapters of this thesis and show how
they are situated within the landscape outlined above.
Chapter 2: Modeling height for children born small for
gestational age treated with growth hormone
In this chapter two approaches of modeling the height of children are compared.
The first is on the original scale, often encountered in the statistical literature. The
second approach to modeling is on the scale of the standard deviation scores,
which is very common in endocrinology. Using data from a trial that evaluated
the effect of growth hormone in children that are born small for gestational age
and remain too small later in childhood, we show that the second approach may
involve more complex modeling and hence a worse model fit.
Chapter 3: A multivariate Bayesian model for embryonic growth
In this chapter, we generalize the SITAR model in a Bayesian way to multiple di-
mensions. This multivariate SITAR (MSITAR)model is used to createmultivariate
reference regions.
The model is illustrated using longitudinal measurements of embryonic
growth obtained in the first semester of pregnancy, collected in the Rotterdam
Predict study. In addition, we demonstrate how the model can be used to find
determinants of embryonic growth.
Chapter 4: Flexible multivariate nonlinear models for
bioequivalence problems
In this chapter we modify the MSITAR model that was introduced in chapter 3
to another setting, a bioequivalence study. In this type of study we want to
demonstrate that the rate and extend at which the active component of a two drug
9
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formulations becomes available to the body does not differ in an important way.
We demonstrate that this model can also be of use to model the concentration
of a drug in the bloodstream. Usually this is done using compartment models,
which are effectively a type of highly nonlinear mixed-effects models when we
the heterogeneity between subjects is taken into account. The MSITAR model
as well as a compartment model are estimated on a real data set containing the
concentration of a test and reference formulation that was measured in the blood
of the antihypertensive drug Losartan. We focus on contrasting the average and
individual bioequivalence .
Chapter 5: Tubular expectile contours
There have been various attempts to generalize quantiles to multiple dimensions.
One idea (that we will adopt) is to reduce a bivariate problem into a univariate
one by projecting the data on a line through the center. When this is done for
multiple directions a reference contour is created. Here we will try and integrate
these bivariate reference regions with the idea of making them depend on a third
variable, thus creating tubular quantile and expectile regions.
Chapter 6: Conclusions and outlook
In this chapter we summarize the main findings from the previous chapters. in
addition we have some proposals for further research.
10
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2 Modelling height for
children born small
for gestational age
treated with growth
hormone
2. Modelling height for children born SGA treated with growth hormone
Abstract:
The analysis of growth curves of children can be done on
either the original scale or in standard deviation scores (SDS).
The first approach is found in many statistical textbooks, while
the second approach is common in endocrinology, for instance
in the evaluation of the effect of growth hormone in children
that are born small for gestational age (SGA) that remain small
later in childhood. We illustrate here that the second approach
may involve more complex modeling and hence a worse model
fit.
Authors: S.P. Willemsen, M. De Ridder, P.H.C. Eilers, A. Hokken-Koelega, & E. Lesaffre.
published in: Statistical methods in medical research (2014)
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2.1 Introduction
Children that are born small for gestational age (SGA) and do not show catch-up
growth are eligible for treatment with a growth hormone (GH). Although there
is some concern that this growth hormone might adversely affect the metabolism,
generally the treatment is considered to be safe and effective [De Zegher et al., 2006;
Hokken-Koelega et al., 2004; Kamboj, 2005]. However, since the cost of treatment
with growth hormone is relatively high [Allen, 2006], it is of practical interest to
know the dose that achieves optimum growth. For children under treatment it is
important to predict their adult height in order to avoid unrealistic expectations.
In this paper, we focus on SGA children treated with growth hormone and
consider (1) modeling of height as a function of age and (2) the prediction of the
adult height. We note that in the endocrinology literature modeling the height is
usually done in terms of the standard deviation score (SDS), see e.g. [Boguszewski
et al., 1998; Cooper et al., 2001; Dalton et al., 2003; De Zegher et al., 2000; Hypponen
et al., 2000; Kamp et al., 2002; Karaolis-Danckert et al., 2006; Kjaergaard et al., 2002;
Nguyen et al., 2004;Ong et al., 2002; Rotteveel et al., 2008]. There is only aminority of
studies that model the untransformed height [Davenport et al., 2002]. A few studies
are based on a combination of both scales [Bakker et al., 2006; Zemel et al., 2002]. In
order to model the growth curve of height y in SDS, for each age the mean and
standard deviation of y need to be established in the reference population. That
is, at age t one determines µ(t , s) and σ(t , s), which are the mean and standard
deviation of y respectively, in the reference population at age t and for sex s. A
variety of techniques can be employed to determine µ(t , s) and σ(t , s) of which
the most prominent seems to be Cole’s LMS method, see [Cole and Green, 1992;
Wright and Royston, 1999]. For most of these techniques some kind of smoothing
is involved. For a new child with height y0 determined at age t0, the height can be
expressed in SDS by computing y0−µ(t0 ,s0)σ(t0 ,s0) with s0 the gender of that child. Note
that the reference population most often consists of children with no diagnosed
growth retardation problems [Fredriks et al., 2000; Van Wieringen and Verbrugge,
1966]. When the distribution of yt ,s is not normal, computation of the SDS is
slightly more complicated, involving a transformation of the raw scores. Here we
will assume that height has a normal distribution conditional on the covariates
(as a conditional normal distribution is often used in practice to model height and
seems to work quite well.)
13
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Presenting the height in SDS allows to conclude readily how remote the child’s
height is from its expected height. Further, for a child belonging to the reference
population, the expected growth curve in SDS is more or less a horizontal line
before it reaches puberty, a phenomenon called ‘tracking’ [Foulkes and Davies,
1981]. Expressing height on the SDS scale aims to produce profiles that are easy
to model. However, for children with an abnormal growth pattern, such as SGA
children, the SDS profile is typically (highly) non-linear. Thus, amodeling exercise
examining factors that influence growth in SGA children will typically be more
complex on the SDS scale than on the height scale. This might adversely affect the
power of the study. Here we illustrate, using data of a double blinded randomized
trial in SGA children conducted in the Netherlands, that it could be preferable to
model the height on the original scale.
To model the growth curves, we used a Bayesian approach with WinBUGS
(version 1.4.3). The advantage of Markov Chain Monte Carlo (MCMC) techniques
over classical non-linear mixed effects maximum likelihood estimation are (1) less
dependence of the modeling exercise on the starting values of the parameters;
(2) more flexibility with respect to distributional assumptions for the random
effects. Further, the Bayesian approach has two additional advantages: (3) taking
into account all uncertainty involving the estimation of model parameters when
predicting characteristics of individual growth curves and (4) the ability to include
prior information into the sampling algorithm. Moreover, (5) Bayesian statistical
inference does not need to be based on large sample arguments but is simply
derived from the posterior distribution of the parameters.
The paper is organized is follows: Section 2 describes the study and the growth
data. In Section 3 we introduce the class of models considered in this exercise. In
Section 4 we apply the models to the data and evaluate the models with regard to
their prediction characteristics. We conclude the paper with a discussion.
2.2 The Dutch growth hormone trial data
The Dutch growth hormone (DGH) trial [Sas et al., 1999; Van Pareren et al., 2003]
was the first randomized double blind trial in the Netherlands that investigated
the effect of the dose of growth hormone treatment on the growth of children
that were born SGA without spontaneous catch-up growth (so they were still too
small at the start if the trial). In this study, SGA is defined as having a birth length
14
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below the third percentile of the normal Dutch population at birth. A number
of factors can cause a child to be SGA such as: intrauterine exposure to toxins,
infections, chromosomal disorders, congenital defects, metabolic diseases and
genetic disorders, the use of tobacco or alcohol by the mother, certain diseases of
themother or certain factors jeopardizing placental perfusion. Often, however, the
exact underlying cause remains unclear [Johnston and Savage, 2004]. SGA children
may show catch-up growth, i.e. while they are initially small, often they grow
faster than other children of the same gestational age such that within their first
year of age their height lies within the 95% normal range. However, some SGA
children experience no catch-up growth and remain too small for their age [Hokken-
Koelinga et al., 1995]. These children may experience several medical problems
later in life such as: an increased risk of developing hypertension, dyslipidemia,
impaired glucose tolerance or diabetes mellitus [Lee et al., 2003].
The DGH trial started in 1991. One group of children was treated with 1 mg
GH/(m2 day) (low dose) and the other with 2 mg /(m2 day) (high dose) of a
synthetic growth hormone (Norditropinr). Inclusion criteria were: boys between
three and eleven years of age or girls between three and nine years of age with a
birth length below -1.88 SDS, a height below -1.88 SDS at the start of the trial (the
SDS scores are computed using the reference values by Roede and Van Wieringen
[1985]), no spontaneous catch-up growth in the last year, pre-pubertal stage and
an uncomplicated neonatal period without severe asphyxia, sepsis or lung prob-
lems. Children with endocrine or metabolic disorders, chromosomal disorders or
growth failure caused by other disorders and syndromes as well as children that
used drugs that could interfere with growth hormones were excluded. Treatment
should be stopped as soon as the child reaches adult height. For this purpose
adult height was defined as the height of a child at the measurement at which the
growth over the previous six months was less than half a centimeter.
In total 79 childrenwere included in the trial, 52 boys and 27 girls. The average
age at the start of treatment was 7 years and 3 months. Nine children dropped
out of the study before reaching adult height: 4 because of lack of motivation,
3 children stopped after they moved, 1 stopped because of signs of precocious
puberty and 1 because of signs of growth hormone insensitivity. For 51 of the 70
children who started growth hormone treatment, an extra height measurement
was taken about five years after the treatment was discontinued. This measure-
ment can sometimes be a little higher than the last regular measurement. No
15
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further measurements where taken after this extra measurement, because the
investigators were convinced that adult height was reached.
The DGH data have been analyzed before. Sas et al. [1999] looked at the height
of the children in the five years after the start of this study by comparing the
average height SDSs between the treatment groups and with the previous year in
all of the first five years of follow up by means of t-tests. The height SDSs were
also compared with -1.88 (the 3rd percentile) to see whether the children were
within the normal range. The authors concluded that almost all children were
within the normal range after five years of GH treatment. Further, there was no
significant difference between the average height SDS of the two dose groups at
the end of the five year treatment period.
Van Pareren et al. [2003] looked at the 54 children that had reached adult height
at the time of their exploration. The average adult height SDS in each treatment
arm was compared with the average height SDS before study, and with zero (to
see whether the mean adult heights are the same as in the reference population).
The mean adult height SDSs were also compared between treatment arms. All
comparisons were done using t-tests. In both groups there was an increase in
average height SDS but not significantly different between the treatment arms. In
the high dose group the average adult height SDS did not differ from zero.
The aims of Sas et al. [1999] and Van Pareren et al. [2003] differ from the aims
in this paper since we want to make use of the whole growth curve to compare
treatment doses. In other words we wish to build a growth curve model for the
heights.
In Figure 2.1 the height profiles of the children participating in the DGH trial
are displayed. The average height in the reference population has been added as
a benchmark. When expressed in SDS the profiles look as in Figure 2.2.
2.3 Statistical models for the height profiles
We consider two growth curve approaches to model height as a function of age:
(1) the untransformed height (in centimeters) and (2) in SDS. All modeling was
done by calling WinBUGS from R using the R2WinBUGS package.
16
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Figure 2.1: DGH trial: height profiles in cm split up according to gender and dose adminis-
tration
Modeling the height in centimeters
Figure 2.1 suggests a suitable structure for a model of height as a function of age.
The height of each child follows an almost linear pattern until the adult height
is reached. On closer inspection, the linearity of the initial part of the growth
curve can be improved upon by a square root transformation of age (as confirmed
by DIC). Hereby the individual growth curves appear approximately as broken
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Figure 2.2: DGH trial: height profiles in SDS split up according to gender and dose adminis-
tration
lines. For this reason, we assumed that the child’s height can be described by an
initial phase of linear growth (in terms of the square root of age) until maturity is
reached at which growth stops and a horizontal line appears. Hence we assumed
that an individual’s growth curve can be described by an intercept, the slope of
the initial phase and the age at which growth stops. Further, we assumed that
these three subject specific coefficients have a trivariate normal distribution with
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a mean possibly depending on sex, treatment dose, age at start of the treatment
and the target height SDS (TH) of the child. The target height is the midparental
height, i.e. the average height of the parents, corrected for the sex of the child and
corrected for the secular growth trend (meaning that on average each generation
is taller than the previous one). To this model measurement error is added. Our
model for height now looks as follows:
yi j  bi1 + bi2 min(ti j − bi3 , 0) + i j ,
bi  (bi1 , bi2 , bi3)Ë ∼ N(µi ,Σb), (2.1)
µik  α0k + α1kSEXi + α2kDOSEi+
α3kSAGEi + α4kTHi (k  1, 2, 3),
i j ∼ N(0, σ2).
In (2.1) yi j is the height of the ith child at agei j , ( j  1, . . . , ni ; i  1, . . . , n), the
age is transformed ti j 
√agei j−√20. Where 20 is the age where all children reach
adult height. bi1, bi2 and bi3 are the subject-specific parameters of the growth curve
of the ith child, and indicate respectively the adult height, slope and change point
for the ith child. The vector bi is assumed to have a trivariate normal distribution
with mean µi and covariance matrix Σb . We assume that µik , the kth component
of µi , is a linear function of covariates with weights αhk , with h  0, . . . , 4. The
measurement error i j is assumed to follow a normal distribution with zero mean
and variance σ2 . Dose is coded as -1 for the low dose and 1 for a high dose, sex is
coded -1 for boys and 1 for girls. SAGEi is the age of entry agei0, approximately
centered by subtracting 7 from it. By centering the covariates, we obtained better
convergence properties for the MCMC chains [Gilks and Roberts, 1996].
Vague and conjugate priors were taken for all fixed effect parameters i.e.
independent normal priors with zero mean and large (106) variance for the αs, an
inverse Wishart prior with 3 degrees of freedom and an identity scale matrix for
the covariance matrix of the random effect parameters b and an inverse gamma
prior with rate 0.001 and mean 0.001 for the residual variance σ2 .
Modeling height on the SDS scale
The growth curves in SDS show a more complex behavior than those on the
original scale. From the profiles in Figure 2.2 we observe that initially the SGA
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children under growth hormone treatment growmuch faster than normal children
of the same age, so their SDS increase. But afterwards the growth rate (in SDS)
slows down. Eventually, the height SDS even decreases, because the children stop
growing at an age where some children in the reference population still continue
to grow.
Because we do not see an obvious structure in the SDS profiles, the mean of
the SDS curves is modeled with a quadratic spline [Ruppert et al., 2003] augmented
with subject specific random intercepts, random slopes and a random quadratic
part. In this way the number of random terms is the same as for the change point
model 2.1. Furthermore, the SDS-growth curves have a quadratic appearance so
a quadratic function seems a logical choice when we want to model the growth
curves with splines with a low number of knots. We have defined ti j as the square
root of agei j after standardization. The number of knots can be increased to make
the model more flexible. We included the same covariates as those for modeling
the height in centimeters. So we have the following model:
ySi j  ci1 + ci2ti j + ci3t
2
i j +
K∑
k1
γk(ti j − κk)2+ + ηi j ,
ci  (ci1 , ci2 , ci3)Ë ∼ N(νi ,Σc), (2.2)
νik  β0k + β1kSEXi + β2kDOSEi+
β3kSAGEi + β4kTHi (k  1, 2, 3),
ηi j ∼N(0, σ2η).
ySi j is the height of the ith child at agei j expressed as SDS with the general Dutch
population stratified by sex as a reference [Roede and Van Wieringen, 1985]. The
coefficients ci1, ci2 and ci3 denote respectively the intercept, slope and quadratic
term for the ith child that are added to the general pattern. The γs are coefficients
of the spline function that do not vary across individuals. The notation, (x)2+
indicates x2 when x > 0 and 0 otherwise. The κks are the knots of the spline.
They are not estimated but fixed and placed at equally positioned quantiles. The
vector ci is assumed to have a trivariate normal distribution with mean νi and
covariance matrix Σc . The mean is allowed to depend linearly on the covariates
through the parameters βhk (h  0, . . . , 4). Measurement error is denoted by ηi j
and is assumed to follow a normal distribution with mean 0 and variance σ2η.
Independent normal priors with zero mean variances of 106 were used for the γs.
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The same vague and conjugate priors were used as for model 2.1 for the other
parameters.
Model comparison
The two longitudinal models were compared in two ways. We compared the fit of
the models by the Deviance Information Criterion (DIC). In addition we compare
the predictive ability using the root mean squared error (RMSE) in prediction.
DIC is a Bayesian generalization of AIC [Spiegelhalter et al., 2002a] and is defined as
Dˆ + 2pD , where D is the deviance and pD is a number that represents the effective
number of parameters in the model. The deviance in turn is defined as minus
two times the log likelihood. By Dˆ we indicate that the deviance is evaluated
at the posterior mean of the parameters. pD is defined as D¯ − Dˆ, the posterior
mean of the deviance minus the deviance evaluated at the posterior mean of the
parameters.
A comparison of the DICs of the two growth curve models involves the
Jacobian since the response differs in the models (or likelihoods). To make the
DICs comparable, we transformed the DIC of model 2.2 to the original height
scale with ySi j 
yi j−µ(ti j ,si )
σ(ti j ,si ) , hence:
log[LS](·)  log[L0](·) +
n∑
i
ni∑
j1
log[σ(ti j , si)], (2.3)
with log[L0](·) the loglikelihoodon theheight scale and log[LS](·) the log-likelihood
on the SDS scale both under model 2.1.
We also compared the models on their predictive ability of the adult height
using the observations before the age of twelve. This comparison was done using
RMSE, defined as
√
1
n
∑n
i1(yi ,A − yˆi ,A)2 where yi ,A denotes the observed adult
height of the ith child. We defined this as the last measurement we observed.
yˆi ,A denotes the posterior mean of the adult height of the ith child based on the
observations of the child before the age of twelve. In model 2.1 we defined the
adult height to be the plateau height that is reached after the change point. In
model 2.2 the adult height was taken to be the height at the age of twenty. To
generate the predictions for the ith child cross validation was applied using a
separate run in WinBUGS for each child. In model 2.1 we used the data of all the
children except the ith (the one we want to predict) to sample parameter values α,
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σ2α,Σb and bi (the random effect parameters for all children except the ith). In each
iteration of theMCMC algorithmwe also sampled the values of the random effects
of the ith child, bi , using both the sampled values of the fixed effects parameters
and the observed height measurements of the ith child that are taken before the
age of twelve. To prevent the observations of the ith child from influencing other
parameters than bi the ‘cut’ function in WinBUGS was used [Spiegelhalter et al.,
2003]. For each sampled value of bi we also computed the change point. For
model 2.2 we computed the RMSE in an analogous fashion.
It would also be interesting to predict not only the adult height itself but also
the age on which it is reached. However because model 2.2 does not give such a
value we could not perform such a comparison.
2.4 Results
For model 2.1, three initially dispersed chains of 30,000 samples were taken from
the posterior after a burn in of the same length. For model 2.2 we took three
dispersed chains of 60,000 samples after a burn-in of 60,000. Convergence was
checked by visual inspection of the trace plots and the Brooks-Gelman-Rubin
diagnostic plots [Gelman and Rubin, 1992].
To check the assumptions of themodelswe performed a number of diagnostics
checks. QQ-plots where produced to check the normality of the random effects
based on their posteriormeans. Further, we compared fitted and observed profiles
and plotted the residuals as a function of age. The assumptions seemed to hold
reasonably well.
Parameter estimates
Parameter estimates (posterior means) and 95% credible intervals for the parame-
ters of model 2.1 are presented in Table 2.1. To aid interpretation the coefficients
are printed in bold whenever the credible interval includes 0. The dose has a
positive effect on the speed of growth, however the adult height was not signif-
icantly different. Quite remarkably, the children that start the therapy at a later
age showed a faster growth and seemed to arrive at a comparable adult height as
children that start earlier. This might indicate that the timing of the start of the
growth hormone therapy is not critical. As we expected, boys attained their adult
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height later and also became taller. Children with a higher target height grew
faster and tended to become taller.
Theparameter estimates and credible intervals formodel 2.2without a spline is
presented in Table 2.2 and thosewith eight interior knots are presented in Table 2.3.
Here it is more difficult to attribute a clear meaning to the individual coefficients.
Because we were mainly interested in the effect of the growth hormone dose, we
computed the effect of dose as a function of age (see the left panel of Figure 2.3).
In principle such plots could also have beenmade for the other covariates but here
we omitted this because of lack of space. From a similar plot for the starting age
we learned that a later starting age leads to results that are just as good as when
therapy is started early as the children grow faster.
The addition of increasingly more knots to the spline allows a more complex
relation between age SDS and height to be fit. In the right panel of Figure 2.3 we
show how the inclusion of more knots to the model changes the average profile.
Table 2.1: Estimated coefficients and associated credible intervals for the model of the
untransformed height scores (Sex is coded -1 for boys and 1 for girls, Dose as -1 for the low
dose and 1 for a high dose)
Level Variable Estimate 95% Credible Interval
Intercept Dose 0.67 [ -0.68 ; 2.10 ]
Sex -5.57 [ -6.79 ; -4.28 ]
Age of Entry -0.19 [ -0.81 ; 0.40 ]
Target Height 3.17 [ 1.77 ; 4.67 ]
Slope Dose 1.31 [ 0.03 ; 2.55 ]
Sex 0.57 [ -0.80 ; 1.81 ]
Age of Entry 2.66 [ 2.08 ; 3.26 ]
Target Height 2.12 [ 0.70 ; 3.51 ]
Change Point Dose -0.01 [ -0.07 ; 0.06 ]
Sex -0.13 [ -0.21 ; -0.07 ]
Age of Entry 0.01 [ -0.02 ; 0.04 ]
Target Height -0.03 [ -0.10 ; 0.04 ]
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Table 2.2: Estimated coefficients and associated credible intervals for the model of the
height SDSs without a spline ((Sex is coded -1 for boys and 1 for girls, Dose as -1 for the
low dose and 1 for a high dose)
Level Variable Estimate 95% Credible Interval
Intercept Dose 0.08 [ -0.10 ; 0.26 ]
Sex 0.08 [ -0.11 ; 0.27 ]
Age of Entry -0.30 [ -0.38 ; -0.22 ]
Target Height 0.51 [ 0.31 ; 0.70 ]
Linear Dose 0.08 [ -0.02 ; 0.18 ]
Sex -0.09 [ -0.19 ; 0.02 ]
Age of Entry 0.23 [ 0.19 ; 0.28 ]
Target Height 0.02 [ -0.09 ; 0.12 ]
Quadratic Dose -0.04 [ -0.12 ; 0.04 ]
Sex 0.01 [ -0.06 ; 0.08 ]
Age of Entry -0.04 [ -0.07 ; -0.00 ]
Target Height -0.02 [ -0.10 ; 0.06 ]
Table 2.3: Estimated coefficients and associated credible intervals for the model of the
height SDSs with a spline with 9 knots
Level Variable Estimate 95% Credible Interval
Intercept Dose 0.07 [ -0.12 ; 0.25 ]
Sex 0.08 [ -0.11 ; 0.27 ]
Age of Entry -0.31 [ -0.39 ; -0.23 ]
Target Height 0.52 [ 0.32 ; 0.72 ]
Linear Dose 0.09 [ -0.00 ; 0.20 ]
Sex -0.16 [ -0.26 ; -0.05 ]
Age of Entry 0.30 [ 0.26 ; 0.35 ]
Target Height 0.01 [ -0.10 ; 0.12 ]
Quadratic Dose -0.04 [ -0.11 ; 0.03 ]
Sex 0.01 [ -0.07 ; 0.09 ]
Age of Entry -0.07 [ -0.10 ; -0.04 ]
Target Height -0.02 [ -0.10 ; 0.06 ]
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Figure 2.3: Average profiles for model 2
Comparing goodness of fit
The DIC (smaller is better) of model 2.1 converted to the SDS scale was -1 831. For
the basic SDS model, i.e. without interior nodes, the DIC was 110. This value can
be improved upon by adding nodes to the spline as can be seen from Table 2.4. It
is clear from this table that model 2.1 always provides a much better fit to the data
than model 2.2 even when a substantial number of nodes are added to the spline.
Based on graphical model diagnostics (not shown) we conclude that the
assumptions of our model are reasonable. From the QQ-plots we saw that the
assumptions of normality for the subject specific effects and measurement errors
hold approximately. When the residuals were plotted against age, we saw that
model 2.1 seemed to fit quite well overall. However the variance seems to be
larger at early ages. In addition at later ages the model seems to yield predictions
that are slightly too low on average. There seemed to be a pattern in the residuals
when no knots are in model 2.2. For model 2.2 involving splines there where no
patterns in residuals. We could extend the models to incorporate non-normality
and heteroskedasticity of the response in our model. However we do not pursue
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this route here as it would distract from the main message.
Table 2.4: DIC (lower is better) of the untransformed height model compared with the
model of the height SDS model with various numbers of interior knots
Model of untransformed height Model of height SDS
Effective df DIC Interior knots Effective df DIC
220.2 -1 831 0 224.0 110
1 226.6 5
2 228.1 -465
3 229.7 -740
4 230.6 -751
5 232.6 -736
6 233.3 -787
7 233.2 -806
8 234.3 -813
9 235.2 -822
Predictive ability
The RMSE of adult height for model 2.1 was 6.9 cm. For model 2 with 9 knots the
RMSE evaluated at 20 years was 8.9 cm. So it appears that model 2.1 performs
better than model 2.2. However, because the height does not remain constant
after a certain age in model 2.2, for the RMSE depends at the age on which it is
evaluated, when an other age than 20 is chosen the RMSE can be larger or smaller.
In contrast in model 2.1 the adult height and hence the RMSE is clearly defined.
Looking at the predicted profiles (see Figure 2.4) we see that in model 2.2 it is
very difficult to predict the change point correctly. In model 2.2 the predicted
profiles are often downward sloping for certain age ranges, which is biologically
impossible.
2.5 Discussion
Often mixed models are used to fit growth curves. Especially in endocrinology
it is customary to do this on the SDS scale. The structure of these models can be
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Figure 2.4: Crossvalidated predicted profiles for selected individuals on the cm scale (0=ob-
served, solid = model 1, dashed = model 2 using 9 knots)
quite complicated. Using the data from the DGH trial we saw that modeling on
the original scale was much easier than on the SDS scale. We obtained a good fit
using less parameters than when working on the SDS scale and with parameters
that are easy to interpret.
It was shown that in our data set that the fit (expressed as the DIC) is better
when we modeled height directly. This is because the structure of the model gets
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complicated when we transform the outcome to SDS scale for reasons that the
studied group of children shows a different growth pattern than the reference
population. When predicting adult height the predictions from the model on the
SDS scale depend on the age at which we evaluate adult height. Furthermore
some of the predicted growth profiles were downward sloping when transformed
to centimeters. Note that the models used give relatively low weight to the adult
height because once a child reaches its adult height it is not measured anymore.
When we would increase the weight of the last measurements, for example by
including pseudo observations equal to the last recordedmeasurement, themodel
on the original scale performed better in prediction.
While there are some advantages to working with the SDS, in this paper we
provide a cautionary note to this standard practice. Depending on the research
question and the group being investigated it dependswhethermodeling should be
doneon theoriginal scale or on the SDS scale. Whenwewant tomake a comparison
with a reference group or compare children across different ages, using the SDS
scale has clear advantagesmaking direct comparisons possible without additional
corrections for age and sex. However in randomized clinical trials where we want
to compare between two treatment groups that are comparable in age and sex
distribution modeling on the original scale can lead to simpler models. This is
especially true if the population being investigated is different than the reference
population or for ages around puberty where the SDS is difficult to interpret.
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3 A multivariate
Bayesian model for
embryonic growth
3. A multivariate Bayesian model for embryonic growth
Abstract:
Most longitudinal growth curve models evaluate the evolution of
each of the anthropometric measurements separately. When applied
to a ‘reference population’ this exercise leads to univariate reference
curves against which new individuals can be evaluated. However,
growth should be evaluated in totality, i.e. by evaluating all body
characteristics jointly. Recently, Cole et al. suggested the SITARmodel
which expresses individual growth curves by three subject-specific
parameters indicating their deviation from a flexible overall growth
curve. This model allows the characterization of normal growth in a
flexible though compact manner. In this paper we generalize the SITAR
model in a Bayesian way to multiple dimensions. The multivariate
SITARmodel allows us to create multivariate reference regions which is
advantageous for prediction. The usefulness of the model is illustrated
on longitudinal measurements of embryonic growth obtained in the
first semester of pregnancy, collected in the ongoing Rotterdam Predict
study. Further, we demonstrate how the model can be used to find
determinants of embryonic growth.
Authors: S.P.Willemsen, P.H.C. Eilers, R.P.MSteegers-Theunissen&E.M. Lesaffre. published
in: Statistics in medicine (2016)
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3.1 Introduction
The statistical analysis of longitudinal growth curves is an active area of research,
with a wide range of applications in medicine, veterinary medicine, biology and
other fields. Many models have been suggested in the literature to fit such data.
When applied to a normal population, the fitted growth curves can be used
to define ‘normal growth’. It is important to detect whether subjects exhibit
normal growth. For example, a good reference of normal fetal growth during
pregnancy can be essential in the management of obstetrical care [Maršál et al.,
1996]. In addition, abnormal growth patterns can be an indication for disease
later in life [Nieto et al., 1992; Cameron and Demerath, 2002]. Many growth models
have a parametric, non-linear nature and are applied to specific application areas.
Examples are the Gompertz curve, the logistic curve or the Brody curve, see e.g.
[Forni et al., 2009].
To relax the parametric nature of the growth curve and hence to broaden the
applicability of the growth curve methodology, Beath [2007] suggested a flexible
approach to model the longitudinal evolution of the growth patterns. This model
was later extended by Cole et al. [Cole et al., 2010a] who called it the ‘Superim-
position by Translation And Rotation’ (SITAR) model. This is a shape invariant
model with a single fitted ‘prototype’ curve. Individual curves are obtained from
the prototype curve by horizontal and vertical shifts and shrinking or stretching
the age scale. However, the model is univariate in nature and therefore cannot
completely capture what normal and abnormal growth is when considering mul-
tiple dimensions. Multivariate growth models have been suggested in the past,
but they either lack flexibility or are difficult to interpret, see e.g. Goldstein [1986];
Reinsel [1982]; Macdonald-Wallis et al. [2012]. In this paper, the SITAR model is
generalized to multiple dimensions and is referred to as the Multivariate SITAR
(MSITAR) model.
To illustrate theMSITARmodel, weuse data fromanongoingpericonceptional
cohort study, called the Rotterdam Predict study, conducted in the Department of
Obstetrics and Gynaecology and the Department of Clinical Genetics at Erasmus
MC University Medical Center, Rotterdam, the Netherlands. In this longitudinal
study human embryonic growth in the first trimester of pregnancy is studied.
Early growth has been a black box for a long time and it was assumed to occur
uniformly, with very small differences between individuals. In fact, this is why
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gestational age (GA) is often estimated from embryonic growth measurements.
The GA is based on the first day of the last menstrual period. However this day
can often not be determined accurately. Lately the idea of uniform growth has
been largely abandoned and the thought has taken root that there are important
differences in embryonic growth in the first trimester [Bottomley et al., 2009; Rou-
sian et al., 2010; Van Uitert et al., 2013; Van Uitert et al., 2014]. Moreover, these
first trimester differences have been related to birth outcomes [Smith et al., 1998;
Mukri et al., 2008; Bukowski et al., 2007; Mook-Kanamori et al., 2010; Carbone et al.,
2012]. Therefore, the study of first trimester embryonic growth has become in-
creasingly important. Further understanding of normal embryonic growth and
the identification of determinants involved will lead to a better and earlier pre-
diction of adverse pregnancy course and future outcomes. Then women with a
family history of adverse birth outcomes may be screened at an early stage and
timely interventions can be made, if necessary. In this respect, it is important to
evaluate growth in its totality and not just look at measurements in separation.
Indeed,measurementsmay appear to evolve in a normalmannerwhen considered
separately but when appreciated in a multivariate sense they may stand out as
abnormal. In statistical terms, such observations are called multivariate outliers.
[Rousseeuw and Van Zomeren, 1990, see]. It is known that such outliers cannot be
identified using univariate techniques. The MSITAR model has the ability to spot
such outlying growth curves, but remains conceptually simple as the univariate
SITAR model.
In Section 3.2, we discuss the motivating data set in more detail and highlight
the research questions that are of interest. In Section 3.3, we describe the SITAR
model exhaustively and show how it can be easily extended to multiple longitu-
dinal series of measurements. In that section we also indicate how multivariate
reference regions can be obtained from the MSITAR model. Marginal and condi-
tional reference contours will be discussed. In Section 3.4 we apply the MSITAR
approach on data of the Rotterdam Predict study. In that section, we will also
contrast the SITAR model applied on each of three parameters to the MSITAR
model applied to the three measurements jointly. In Section 3.5 we give some
concluding, clinical and statistical remarks. We also outline further extensions of
our model.
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3.2 Motivating Data Set: The Rotterdam Predict
Study
The Rotterdam Predict study is a periconceptional cohort study carried out at
the Department of Obstetrics and Gynaecology at Erasmus MC, Rotterdam, the
Netherlands. The overall aim of the study is to examine early human growth and
to determine factors associated with complications originating in the periconcep-
tional period and the early stages of pregnancy. The Rotterdam Predict study [Van
Uitert et al., 2013] is the first of its kind in which the early pregnancy is studied
meticulously. In addition to regular, 2D, ultrasound images, three dimensional
(3D) ultrasound images are taken.
Every week between the sixth and the thirteenth week of pregnancy, each
participating woman receives a 2D and a 3D ultrasound. From these ultrasound
measurements, the crown-rump length (CRL), total arc length (TAL) and the
embryonic volume (EV) are determined. The CRL is defined as the shortest
distance from the crown (top of the head) to the rump (buttocks). The CRL is
one of the most important measurements made in early pregnancy as it is often
used for pregnancy dating. The TAL is another measure of the distance between
crown and rump introduced by Boogers et. al. (unpublished manuscript), but
now determined on the outside of the embryo along the dorsal side of the back
as depicted in Figure 3.1. The relation between CRL and TAL is a function of the
gestational age (GA), which is defined as the number of days since the first day of
the last menstrual period (LMP).
The embryonic volume ismeasured based on the 3Dultrasound images. Using
the 3D images, holographic projections of the embryo are made in the Barco I-
Space (Barco N.V., Kortrĳk, Belgium). Using the V-Scope software an interactive
projection ismade on the floor andwalls using eight projectors in away that allows
depth-perception using stereoscopic imaging [Koning et al., 2009]. From this image,
the EV of the embryo was determined based on the grey-level of the voxels (3D
pixels) of the embryo. It has been suggested that EV gives a better indication of the
GA than CRL Rousian et al. [2010]. In addition EV is believed to be an important
parameter to detect growth disorders [Rolo et al., 2009]. Unfortunately, not all
measurements could be performed using the 3D images because the holographic
projector is an expensive piece of equipment that is also used for other research
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in Erasmus MC.
For this studywomen above the age of 18 and before the 8thweek of pregnancy
were recruited. The cohort is not a random sample of the general population.
Rather,womenweremade aware of the studybyposters placed in theGynaecology
and Obstetrics outpatient clinic of the Erasmus MC. A part of the women (23%)
did not go to the Erasmus MC outpatient clinic prior to inclusion, but learned
about the study through word-of-mouth. As a consequence, the women included
in the cohort are likely to have a higher risk of pregnancy complications.
We included 259 eligible singleton pregnancies in the Rotterdam Predict study
between 2009 and 2010. 44 womenwere excluded because of ectopic pregnancy or
miscarriage occurring before the 16th week of gestation. These pregnancies were
excluded because the course of the pregnancy was different than from regular
pregnancies and we are only interested in normal healthy pregnancies. Another
12 pregnancies were excluded because they could not be dated based on the LMP.
This leaves 203 pregnancies for the analysis.
Finally, not all of the images couldbeused for allmeasurementsmostly because
of a low image quality or an unfavorable position of the embryo. There are on
average approximately 5 available measurements per pregnancy for the CRL and
the TAL measurement and approximately 4 measurements for the EV. The EV
is often more difficult to measure accurately because sometimes the volume of
the fetus cannot be clearly separated from its surroundings on the ultrasound.
However, in some cases EV could be determined while CRL or TAL could not be
measured.
In Table 3.1 we provide some characteristics of the study sample which re-
veals that the participants are predominantly highly educated. Because they are
recruited mostly from a tertiary hospital they are at a higher risk for pregnancy
complications. Therefore, one cannot immediately extrapolate the results of this
study to the general population. As a comparison, in the regular hospital popu-
lation in the Netherlands about 16% of the women giving birth is of non western
origin, about 51% is nulliparous and the median age is between 30 and 34 years
De Graaf et al. [2010]. Notice that we do have some missing values for some vari-
ables. The cases with missing data include two cases where the pregnancy was
conceived after oocyte donation. For these cases, the relation between maternal
characteristics and growth is likely to be different than in regular pregnancies. In
addition, there are ten pregnancies for which one or more of the covariates wewill
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Table 3.1: Descriptive statistics of the selected women from the Predict study (n=203).
Characteristic Mean / N (SD/ %)
Age 32.2 ( 4.8)
Missing 11 ( 5%)
Ethnicity
Dutch 150 (74%)
Other western 16 ( 8%)
Other non-western 30 (15%)
Missing 7 ( 3%)
Education
Low 18 ( 9%)
Middle 56 (28%)
High 113 (56%)
Missing 16 ( 8%)
BMI 24.6 ( 4.1)
Missing 8 ( 4%)
Parity
Nulliparous 124 (61%)
Multiparous 74 (36%)
Missing 5 ( 2%)
Periconceptional alcohol use
Yes 87 (43%)
No 109 (54%)
Missing 7 ( 3%)
Periconceptional smoking
Yes 31 (15%)
No 165 (81%)
Missing 7 ( 3%)
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B. TAL
A. CRL
Figure 3.1: Illustration of CRL and TAL: the head of the fetus is on the left and the curved
line represents its back. The distance A is the CRL and the distance B is the TAL
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Figure 3.2: Scatterplots of the ultrasound measurements taken in the first three months of
pregnancy. Three randomly selected pregnancies are indicated. The estimated profiles for
these individuals are obtained from the MSITAR model (See Section 3.4)
consider are missing. So for analyses that use covariates we have 191 pregnancies
left. We could also have imputed the missing values within the MCMC scheme.
However this increases computational complexity. Because we feel it distracts
from the main idea of the paper we did not follow this path.
Here we use the Rotterdam Predict study to illustrate how the multivariate
SITAR model can be used to model human embryonic growth. In particular we
indicate that our model is better capable to detect abnormal pregnancies.
In Figure 3.2 we show scatter plots of the three features of embryonic growth
versus GA, wherein some randomly selected growth profiles are highlighted.
Note that we plotted EV on a logarithmic scale. Clearly there is a large amount
of correlation between the measurements of each pregnancy, both within each
separate outcome but also between the different series.
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3.3 The SITARModel
The univariate SITAR model
The SITAR model is based on the ’Shape invariant’ model of infant growth
suggested by Beath [2007]. The idea behind the model is that there exists some
general growth curve, or prototype function, f () such that all individual growth
profiles can be reduced to this general curve by translating them horizontally and
vertically and by stretching them horizontally. So we have yi j  γi2 + f (γi3[ti j +
γi1]) + εi j . where yi j is the outcome of individual i measured at time ti j . The γs
are the subject specific effects and express the subject-specific horizontal shift (γi1),
the vertical shift (γi2) and the stretch (γi3) with respect to the general growth curve.
εi j is the measurement error. See Figure 3.3 for a schematic representation of the
effect of the random effects. Note that stretching the general curve horizontally
is something that is related to accelerated failure time models in which the scale
parameter has a similar role as γi3.
In the SITAR model, the curve of the general pattern is modeled by a natural
cubic spline function. A spline of degree d is a smooth function that is piece-wise
constructed from polynomials of degree d. For a cubic spline this degree is three.
The points where the polynomial functions join are called the inner knots, while
the knots at the boundary are the outer knots. A spline is called ‘natural’ when
the second derivative at the outer knots of the spline is zero. The spline can then
be linearly extrapolated beyond the outer knots. Proper extrapolation is needed
since the horizontal shifts imply that the domain in which the splines will be
evaluated are not exactly known beforehand. With κ inner knots the natural cubic
spline has κ + 2 independent coefficients.
Now the univariate SITAR model can be expressed as:
yi j  γi2 + zTi jβ + εi j ,
zi j  B
(
exp(γi3)(ti j + γi1)) , (i  1, . . . ,N ; j  1, . . . , ni), (3.1)
γi ∼ N(0,Σγ),
εi j ∼ N(0, σ2).
Wemade the assumption here that γi  (γi1 , γi2 , γi3)T is normally distributed and
its components are centered at zero to avoid identifiability problems. B(t) is a
function that returns the basis of the natural cubic spline, evaluated at t. Thus, zi j
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Figure 3.3: Schematic representation of SITAR model with horizontal shift (γi1), vertical
shift (γi2) and stretch (γi3)
is a vector of length κ+ 2, as is the regression coefficient vector β. We also assume
that εi j is independently distributed with variance σ2 and independent of the γs.
The SITARmodel has been successfully applied to different data sets, appears
to work well in practice and has parameters that are easily interpretable by
clinicians [Cole et al., 2010a].
The multivariate SITAR model
The univariate SITAR model can be easily extended to K(> 1) outcomes. The
multivariate SITAR model (MSITAR) is given by:
yi jk  γi2k + zTi jkβk + εi jk ,
zi jk ≡ zi jk(γMi )  B
(
exp(γi3k)(ti jk + γi1k)
)
, (3.2)
(i  1, . . . ,N ; j  1, . . . , nik ; k  1, . . . , K),
γMi ∼ N(0,ΣMγ ),
εi jk ∼ N(0, σ2k),
where yi jk is the kth response of individual i at time ti j , zi jk a basis of a natural
cubic spline for the kth response of individual i at time ti j , βk the vector of spline
coefficients for the kth response, γilk (l  1, 2, 3) are the three subject specific
effects for individual i and series k (k  1, . . . , K) , γik  (γi1k , γi2k , γi3k)T is the
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vector of all subject specific effects for outcome k and individual i. When we
combine the subject specific effects for all outcomes for an individual we obtain
γMi  (γTi1 , . . . , γTiK)T . ΣMγ is the 3K × 3K joint covariance matrix of all random
effects γMi . εi jk is the measurement error which we assume to be independently
distributed and independent of the γs. Finally, σ2k is the measurement error
variance for series k. Note that it is assumed that the K outcomes are independent
given the random effects.
The multivariate SITAR has the advantage over the univariate SITAR model
that the three series of measurements can be modeled jointly. In general, joint
modeling of multiple series of growth curves allows for:
• Evaluating relationships between the growth curve series over time.
• Establishing multivariate reference regions and thereby checking whether
individuals not only show a normal growth pattern for an individual series
but also for, e.g., ratios of series.
• Better prediction of a future growth profile of a series when no or few past
observations are available by also incorporating information from the past
profiles of other series.
We were also interested in the effect of covariates on the parameters of the
model. That is, we assumed that the means of the γs could depend on covariates.
Let xi be the vector of covariates for subject i of length np . We then assume that
γMi ∼ N(Axi ,ΣMγ ). Here A is a 3K × np matrix of parameters with elements αk ,p .
We will also use the notation α to denote vec(A)  (α1,1 , α2,1 , . . . , α3K,np )T , which
is the vectorized form of the matrix A, that is the column matrix that consists of
the columns of A that are stacked on top of each other.
MCMC implementation
We used a Bayesian approach to estimate the model parameters, employing
vague priors for all parameters. When possible we also opted for priors that are
conditionally conjugate. Specifically, we assumed for the αs and βs independent
normal priors with zero mean and a standard deviation equal to σα,0  σβ,0 
1, 000, which is large relative to the plausible values of α and β. For σ2 an inverse
gamma prior was chosenwith shape parameter (ασ) and rate parameter (βσ) equal
to 0.001, i.e. IG(0.001, 0.001). Finally, for ΣMγ we have chosen an inverted Wishart
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prior with degrees of freedom δ equal to three times the number of outcomes
and a scale matrix Ψ equal to 0.01 times the identity matrix, i.e. IW(3K, 0.01I3K).
For a motivation of these choices see Lesaffre and Lawson [2012, p. 260]. As more
(external) information is collected on growth during early pregnancy, we believe
that in due time some of these vague priors may be replaced bymore oinformative
priors.
The posterior distribution is proportional to the product of the likelihood and
the priors, and therefore we obtain:
p(α, β, σ2 , γM ,ΣMγ | y) ∝
∏
i jk
N(yi jk | γi2k + zi jk(γMi )Tβk , σ2k)×∏
i
N(γMi | 0,ΣMγ )× (3.3)∏
k
N(αk | 0, σ2α,0 Inp )
∏
k
N(βk | 0, σ2β,0 Iκ+2)×∏
k
IG(σ2k | ασ , βσ) IW(ΣMγ | δ,Ψ),
with β  (βT1 , . . . , βTK)T , σ2  (σ21 , . . . , σ2K)T , γM  (γM1 , . . . , γMN )T and y 
(y111 , y121 , . . . , y1ni1 , y211 , . . . , yN,nNK ,K)T .
We implemented a Gibbs sampling procedure to estimate the model param-
eters. The (block) full conditionals for β, α, σ2k and ΣMγ are given in the supple-
mentary material. Most full conditionals are of standard form and hence standard
samplers can be used. However, this is not the case for the full conditional
distribution of the subject specific effects, given by:
γMi |y , . . . ∼ N3K(γMi | Axi ,Σγ)×∏
j,k
N(yi jk | γi2k + B(exp(γi3k)(ti j + γi1k)βk), σ2k), (3.4)
where a Metropolis step is needed.
The above model can be estimated in JAGS [Plummer, 2003a]. We also imple-
mented the sampler directly into C++ making use of the ‘Eigen’[http://eigen.
tuxfamily.org/] and ‘Boost’ libraries [http://www.boost.org/]. By em-
bedding the program into the R language its output can be post-processed with
R functions, such as CODA [Plummer et al., 2006]. For the full conditionals of the
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subject specific effects, we used in the C++ program a Random Walk Metropolis
algorithm with a multivariate t proposal distribution with 5 degrees of freedom.
The acceptance rate of the Metropolis algorithm was tuned so that it was approxi-
mately 30%. The source code of our programs can be obtained upon request from
the first author.
Model selection and evaluation
Model selectionwas done using the popular Deviance Information Criterion (DIC)
[Spiegelhalter et al., 2002b]. More specifically, we compared the MSITAR model to
the ensemble of univariate SITAR models to check the necessity of modeling the
three series of growth curve responses jointly.
To check the assumptions of our model, we performed posterior predictive
checks (PPC). That is, based on the estimated model we simulated replicated
series. We then compared the distribution of the test statistic calculated on the
replicates with the test statistic based on the data which we actually observed.
Specifically we looked at the chi-squared goodness-of-fit test recommended by
Gelman et al. [1996]. That is, we drew posterior samples for each of the K outcomes
χ2GM,k 
∑
i , j
r2i jk with ri jk 
yi jk − E(yi jk | θ˜)
sd(yi jk | θ˜)
(3.5)
and compared it with χ2GM,k ,rep obtained from replacing yi jk by the correspond-
ing sampled value y˜i jk from the posterior predictive distribution (PPD) in (3.5),
p( y˜i jk |y). In this expression θ˜ stands for the sampled total parameter vector and
E(yi jk) is defined as B(γ˜i3k(γ˜i1k + ti jk))β˜k + γ˜i2k . We then checked the proportion
of samples in which χ2GM,k ,rep > χ
2
GM,k . In a similar way we computed the PPC
evaluating the skewness and kurtosis of the error terms εi jk . For instance, the
statistic χ2SKEW,k 
∑
i , j r3i jk checks the skewness of the errors, which we assumed
zero.
Finally, we extended the model so it could accommodate a residual error with
excess kurtosis. Specifically, we have replaced the normal residual error by a
scaled t-distribution. In our C++ program we simulated from a t-distribution by
considering it as a scale mixture of normals. We considered the inverse of the
number of degrees of freedom to be uniformly distributed on [0, 13 ]. With this
41
3. A multivariate Bayesian model for embryonic growth
prior we give a larger prior probability to smaller numbers of degrees of freedom,
that is to distributions that are further away from the normal.
Predictive ability of the model
The predictive ability of the models was evaluated by the root mean squared pre-
diction error (RMSE). We want to know, once we have an estimated model, how
well it can predict a future observation of a newpregnancy given the availablemea-
surements of this pregnancy. This was evaluated using five-fold cross-validation,
whereby the total data set was split into five (approximately) equal parts, each
containing 20% of the pregnancies. Each time 80% of the observations served
as training set and the remaining 20%-part as validation set. In the validation
part, we removed the last value for each combination of pregnancy and outcome,
which we will denote by yik ,LAST, which is to be predicted. In the supplemental
material we provide the details of the procedure we used to draw samples from
the predictive distribution of this last observation. We then took the mean of
these samples for each i and k, denoted by yˆik ,LAST and calculated the RMSE as√∑Nk
i1(yik ,LAST − yˆik ,LAST)2/Nk). Here Nk is the number of pregnancies for which
we observed the kth outcome.
Reference contours
Our model allows for the construction of multivariate reference ranges. With a
single outcome a reference range is a central predictive interval in which 100(1-
q)% of the observations are located. Often equal-tail predictive intervals are
taken. This can be generalized to multiple dimensions so we obtain a reference
region excluding the most outlying observations and containing the least outlying
observations (or for lack of a better word the ‘normal’ observations). However
such an extension is not trivial since univariate quantiles are not easily adapted
to the multivariate case [Serfling, 2002]. Here we followed the approach of Kong
and Mizera [2008] and look at contours obtained from a collection of directional
quantiles. For a direction indicated by a unit vector s, the qth directional quantile
in the direction of s, i.e. Q(q , s) of a multivariate random variable y is defined as
the quantile of sT y, which corresponds to the orthogonal projection of y on s. To
construct the directional quantile contour Q(q), one varies the direction given by
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the vector s to cover all angles. EachQ(q , s) defines a half-spacewhere 100(1−q)%
of the observations lie. By taking the intersection of these half-spaces one obtains
the contourQ(q), see Figure 3.4 for a graphical representation of this construction.
Note, however, that in this figure only a limited number of directions s has been
taken to enhance the legibility of the figure. In general, Q(q) will exclude more
than a fraction q of the observations. A contour that excludes a fraction q of the
observations is then obtained by an optimization routine to find a value q′ for
which Q(q′) does have this property.
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Figure 3.4: The construction of directional quantiles.
To generate the directional quantile contours based on our model, we gener-
ated samples y for a new individual from the posterior predictive distribution of
our model and drew a large number of directional quantiles based on this sample.
This results in unconditional or marginal contours. It is also possible to derive
conditional contours, i.e., when there is interest in the expected range of future
‘normal’ outcome values for subjects given their history (i.e. past covariates and
responses). These values can be generated in much the same way as the uncon-
ditional ones. The difference is that we now sample γMi from the conditional
distribution (3.4) of those individuals given their history.
Conditional quantile contours can also be constructed based on the distribu-
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tion of the residuals in a way that avoids sampling. For example, if a multivariate
outcome is (conditionally) multivariate normal, the probability contours are ellip-
tical. However this fails to take the uncertainty in the parameter estimates into
account properly. We believe this is important in a clinical setting when limited
information is available and parameter uncertainty is relatively large.
Effect of time scale
The γi3k random effects result in stretching the time axis in order to, together with
the other random effects, align the curve of the ith individual with the overall
‘mean’ smooth curve. We argue that this stretch effect is most effective when
the first measurement of each individual is taken just after time zero. When the
origin of the time axis is remote from the measurement times the stretch effect is
rather similar to the horizontal shift effect, so sampling becomes more difficult.
However, in human embryonic growth studies, measurements cannot be taken
at conception. In fact, in the Rotterdam Predict study, the first measurement was
taken between days 40 and 50 since no reliable measurements can be made before
this time with the current techniques. For this reason, model (3.2) is based on
the GA minus 36 days. In this way the transformed GA at the first occasion that
measurements could be taken is small but positive. In general, when we apply a
linear transformation on the time scale, we have: t˜i jk 
ti jk+a
b so the second line
of model (3.2) becomes zi jk  B˜(exp(γ˜i3k)(t˜i jk + γ˜i1k). Here B˜ is a new spline
function that is created by applying the same linear transformation on the nodes
of B. When we only change the time scale the effect is similar to increasing the
prior variance of the horizontal shifts by a factor
√
b. The effect of a is to change
the origin of the time scale. In this case the effect of the transformation is more
profound and finding an appropriate prior would be much more complicated
than changing the time scale. In theory optimal a and b could be estimated from
the data by treating them as extra parameters. However, we have chosen here not
to do so to avoid further computational complexity.
3.4 Analysis of the motivating data set
In this section we present the results of our analysis. First we estimated the SITAR
model separately for each of the three series (CRL, TAL and EV) and looked at the
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correlation between the subject specific effects obtained in these models. We then
estimated the joint model for all the outcomes together. In the next subsection
we focus on the inclusion of covariates. In all analyses we used κ  3 with
equidistant nodes, which provided enough flexibility for the prototype growth
curve. The univariatemodels were run for 600,000 iterations (with 300,000 burn-in
iterations) and the multivariate model for 1,200,000 iterations (with 600,000 burn-
in iterations). For all models three chains were initiated with different starting
values. Convergence was checked visually by examining the trace plots of the
Markov chains and more formally by the Gelman and Rubin [Gelman and Rubin,
1992] test. The effective sample size ranged from approximately 1,200 for the β
values to 11,000 for the σ2 values. On an Intel i5-24000 processor running at 3.1
GHz with 8 GB RAM and the 64 bit version of Windows, the time needed to run
1,200,000 iterations for the multivariate model was approximately 18 hours.
Univariate analyses
Weuseda logarithmic transformation for all responses. This reducedheteroscedas-
ticity in the responses and also ensures that predictions are always positive. Note
that the vertical shift on the log scale corresponds to a stretch effect on the original
scale.
We wanted to investigate the relation between the subject specific effects
that belong to the same pregnancy. Therefore we have made scatterplots of the
components of the posterior means of the centered effects. By centered effects we
mean the deviations of these effects from there expected values (ie. γM − XAT).
In Figure 3.5 we organized the scatterplots of pairs of variables into six scatterplot
matrices. In the upper triangular part of each scatterplot matrix we show the
pairwise scatterplots of the posterior mean of the centered random effects within
the same series (subplots a–c), and the scatterplot between similar effects in
different series (subplots d–f). The correlation between the horizontal and vertical
effects is always negative. Other than that, there does not seem to be an obvious
pattern in the correlations of each outcome. When we look at the correlation
between similar effects of different outcomes the very strong correlations of 0.9
between the horizontal shifts stand out (See subplot d). The other correlations
are smaller but still positive (0.1–0.4). The relative size of the horizontal shifts,
(compared to their sd’s, which are not shown here), appear greater than those of
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the vertical and stretch effects.
In Table 3.2 we show the results of the posterior predictive checks. Here
numbers close to either zero or one indicate that model assumptions might not
be met. As is obvious from the leftmost columns of this table there are some
deviations from the model assumptions when we assume a normally distributed
measurement error. The residuals appear to be platykurtic distributed. This
could be remedied by replacing the normal residual error by a t-distribution (this
is illustrated in the rightmost part of the table). The posterior mean of the degrees
of freedom were 4.9, 3.9 and 3.5 for the CRL, TAL and EV respectively. In the
SupplementaryMaterial we provideQ-Q plots of the subject specific effects. There
appear to be some, relatively minor, deviations from normality. In particular the
stretch-effect of the TAL seems to have heavier tails than expected. An obvious
way to remedy this is also to change the distribution of the subject-specific effects.
Unfortunately we were unable to fit a model where both the subject specific effects
were non-normal. Because changing the residual errors to a scaled t-distribution
also improved the Q-Q plots of the subject specific effects, we continued with this
model.
Table 3.2: Posterior predictive checks of the univariate SITARs
PPC: Normal errors PPC: t-distributed errors
CRL TAL EV CRL TAL EV
χ2GM 0.48 0.52 0.49 0.48 0.35 0.45
χ2SKEW 0.27 0.12 0.52 0.41 0.22 0.78
χ2KURT 0.00 0.00 0.00 0.69 0.61 0.90
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(f) Stretch Effects
Figure 3.5: Scatterplots of the posterior means of the subject specific effects γM − XAT
from the univariate model (upper triangular) and multivariate model (lower triangular).
’H’ denotes the horizontal shift, ’V’ the vertical shift and ’S’ the stretch effect
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Multivariate analysis
We then estimated the joint model for all three series together, i.e. the MSITAR
model. For this we used the results of our univariate models as starting values
of the sampling procedure. The scatterplots of the subject specific effects within
each series are shown in the lower triangular subplots of Figure 3.5a–c. The points
have slightly fanned out. This is most evident in the vertical and shift effects in
the CRL and TAL (see subfigures a and b). The correlation between the horizontal
and vertical effects is still negative like in the univariate models. Again, there does
not seem to be a pattern in the correlations that involve the stretch effect. Most
correlations have the same sign as in theunivariate case. Notable exceptions are the
relations between the stretch effect and the two other effects in the CRL (Compare
the rightmost column and bottom row of subfigure 3.5a). In Figures 3.5d–f we
show the scatterplot of similar subject specific effects between similar effects in
different series. In subfigure 3.5d we see that, like in the univariate models, the
correlation between the horizontal effects is strong (around 0.9). The correlation
between the vertical shift and the stretch effects has also become stronger when
compared with the univariate models (see subfigures 3.5d and f). As for the
univariate models we found some deviations from the model assumptions with
the posterior predictive checks (see Table 3.3). Again the observed kurtosis
does not match that of the normal distribution. When we replaced the normal
distribution with a t-distribution, this problem was solved for CRL and TAL.
However, the t-distributions seem to be unable to accurately model the kurtosis
of the EV. The posterior mean of the degrees of freedom where 4.5, 4.0 and 3.3
for the CRL, TAL and EV respectively. For three pregnancies we have plotted the
estimated profiles based on the MSITARmodel with t-distributed errors in Figure
3.2. The estimated profiles from the model with a normal error look very much
like these ones and are not shown.
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Table 3.3: Posterior predictive checks of the multivariate SITAR models
PPC: Normal errors PPC: t-distributed errors
CRL TAL EV CRL TAL EV
χ2GM 0.50 0.48 0.19 0.50 0.28 0.04
χ2SKEW 0.37 0.14 0.25 0.22 0.15 0.53
χ2KURT 0.00 0.00 0.09 0.21 0.70 1.00
Comparison of the univariate and multivariate models
We compared the collection of the three univariate models with the MSITAR
model using DIC.We obtained for the multivariate model a DIC of -7,222 with 922
effective parameters (pD). This value is substantially smaller than for the collection
of univariate models for which the DIC is -6,785 with pD  1, 030. Hence the
MSITAR model is preferred.
Table 3.4: Root mean squared prediction error of the ensemble of SITAR models and the
MSITAR model (both with normal and t-distributed error (MSITAR-T))
RMSE
Variable SITARs MSITAR MSITAR-T
log(CRL) 0.051 0.053 0.052
log(TAL) 0.042 0.043 0.044
log(EV) 0.172 0.171 0.172
log(CRL/TAL) 0.042 0.041 0.042
In Table 3.4 we compare the RMSE between the univariate and multivariate
models. The RMSEs largely agree. So from these results we must conclude that
there does not seem to be any benefit in using the MSITAR model for prediction.
However, this general conclusion overlooks some special situations that are highly
relevant in practice. Indeed, one advantage of the multivariate model is that it
also enables us to make predictions for one of the outcomes when no previous
measurements on that kind of outcome are available. For an example we refer
to the EV of the pregnancy marked with ‘triangles’ in Figure 3.2. The reason is
that in the MSITAR model the correlation among the series is used to predict the
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responses of the missing series while in the univariate models there is nothing
that can provide this information. Even when we have an outcome for which we
have only a single previous measurement of the same outcome as the outcome
whichwewant to predict, themultivariatemodel does slightly better. For example
when we predict the last measured EV in those pregnancies where we had only
one or two previous observations the RMSE of the multivariate models was 0.29
vs 0.33 for the univariate model. For the CRL and the TAL we have more than 2
observations for almost all of the pregnancies.
Covariates
Using the MSITAR model we aimed to look at the effect of periconceptional con-
ditions such as maternal age, nulliparous pregnancies (i.e. first-time pregnancies),
smoking and alcohol use of the mother and maternal BMI on CRL, TAL and EV.
All continuous covariates were standardized while for the binary variables we
used effect coding. In Table 3.5 we show the estimated coefficients. Here we only
show the estimated coefficients from the MSITARmodel with t-distributed errors,
however the results are similar for the univariate models and models with normal
distributed errors. We see that the pattern of the coefficients is similar across the
different outcomes. It seems that the horizontal effects are most ‘significant’.
While the parameters have an obvious meaning, a predictor can influence the
response of an outcome in multiple ways. For example smoking at the same time
causes children to be ‘slow’ (ie. behind the curve) and bigger. Therefore, to better
appreciate the effect of a particular covariate we plotted the ‘average’ profiles for a
typical pregnancy. In Figure 3.6 we have graphically shown the effect of smoking
on the three series.
Reference contours
Unconditional reference contours allow us to determine the range of ‘normal’
ultrasound images at a particular GA for a new pregnancy. In Figure 3.7 we
demonstrate how these contours can be constructed. First, one generates a sample
of y for a new individual from the estimated MSITAR model and draws all direc-
tional quantiles based on this sample. This is illustrated in Figure 3.7(a) where
we have simulated values for CRL, TAL and EV for an embryo of 53 days old
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Table 3.5: Regression coefficients (posterior means and standard deviations) of theMSITAR
model
CRL
Horizontal effect Vertical effect Stretch effect
Coef SE Coef SE Coef SE
Maternal age 0.045 0.021 0.017 0.014 -0.0060 0.0074
Nulliparous pregnancy-0.056 0.021 0.021 0.013 -0.0028 0.0071
Smoking -0.085 0.025 0.021 0.017 -0.0085 0.0086
Alcohol use -0.006 0.024 -0.023 0.013 0.0075 0.0068
BMI 0.025 0.022 -0.013 0.013 0.0018 0.0068
TAL
Coef SE Coef SE Coef SE
Maternal age 0.071 0.022 0.009 0.009 -0.0089 0.0056
Nulliparous pregnancy-0.053 0.022 0.021 0.009 -0.0069 0.0056
Smoking -0.091 0.026 0.028 0.011 -0.0169 0.0075
Alcohol use -0.004 0.022 -0.017 0.008 0.0050 0.0054
BMI 0.008 0.024 0.002 0.009 -0.0048 0.0057
EV
Coef SE Coef SE Coef SE
Maternal age 0.048 0.019 -0.012 0.072 0.0046 0.0170
Nulliparous pregnancy-0.033 0.019 0.021 0.063 0.0014 0.0155
Smoking -0.054 0.023 0.205 0.074 -0.0563 0.0185
Alcohol use -0.008 0.020 0.087 0.056 -0.0283 0.0136
BMI 0.019 0.019 0.052 0.076 -0.0145 0.0185
from the Rotterdam Predict study. Note that this pregnancy appears quite normal
univariately with a CRL of 1.45 mm and a TAL of 2.06 mm, but becomes rather
unusual when we look at it bivariately. Note also that the fraction of the sample
that is outside of the contour of the 5% directional quantiles is actually larger
than 10%. As a reference, we have also plotted the quantile contour that does
encompass 90% of the observations. Another way to visualize how ’normal’ a
certain observation is to plot the minimum directional quantile and the direction
in which this minimum is reached, i.e. the pair (mins(Q(q , s)), argmins(Q(q , s))
This is done in Figure 3.7(b). By connecting the values observed at different time
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Figure 3.6: Effect of smoking
points, as is done in Figure 3.7(c), one can visualize the trajectory of an individual
pregnancy relative to the whole group. In this case we see that although the
pregnancy is quite outlying at the start, it becomes more ordinary later.
For a conditional reference contour, prediction is done assuming that we
already have a number of ultrasound images from a certain pregnancy as well as
background information such as smoking status, alcohol use and maternal age.
Now we wish to know what measurement values would be considered as normal
at a future time point. We again simulate replicate observations from the model
but now we use the full conditional (3.4) to simulate the subject specific effects
taking into account all the information we have for this pregnancy. Plots of the
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(c) Following an individual over time
Figure 3.7: Reference contours
conditional reference contours and the evolution of the multivariate quantile over
time can be made in much the same way as for the unconditional contours and
quantiles and are therefore not shown here.
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Simplifying the random effect structure
Triggered by the high correlation between the horizontal effects we investigated
if it would be reasonable to assume that these parameters are the same in each of
the separate growth curves. Indeed when we simplified the model in this respect
the DIC improved by 70 points in the model with normally distributed errors and
by 15 points in the model with t-distributed errors.
3.5 Discussion and conclusions
We have extended the SITAR model of Cole et al. to include several outcomes,
which we refer to as the MSITAR model. The model is quite flexible in modeling
different growth patterns while at the same time remaining easy to interpret. In
this paper we have applied this model on embryonic growth data, however it can
also be used to model other kinds of growth data and even in completely different
fields of study.
We have shown that the MSITAR model provides a better fit to the data of the
Rotterdam Predict Study than the collection of univariate SITAR models. Oddly
enough this does not result in an improved predictive ability. However a benefit
of the MSITAR model is that, in case we have missing values in one of the series,
we can recover some of that missing information from the other series. This is very
relevant in a clinical settingwhere it is impossible tomake frequentmeasurements
of all outcomes. By means of the MSITAR model we can predict future values
for an outcome when we have a single previous measurement for that outcome
or even no previous measurements at all as long as we have measurements for
other outcomes. Furthermore, the MSITAR model enables one also to look at the
relation between the various series which is useful on its own.
Surely other techniques suitable to model flexibly multivariate longitudinal
data are available, see e.g. [Xu et al., 2008; Rosen and Thompson, 2009; Macdonald-
Wallis et al., 2012]. However we argue that the parameters of these models are less
interpretable than those of the MSITAR model. A related technique is formed by
the class of three-mode models discussed in [Oort, 2001]. This approach requires
balanced measurements, which is often not the case in growth studies.
We have successfully used the MSITAR model to assess various potential
determinants of embryonic growth. However because all three types of effect
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influence the outcome simultaneously, we have to calculate the net effect at differ-
ent time points as we did in Section 3.4, which diminishes the usefulness of the
interpretation of the γ parameters.
The Bayesian procedure lends itself to the construction of reference contours
in which all parameter uncertainty is taken into account. These can be used to
detect multivariate outliers that would otherwise go unnoticed. Furthermore
covariates and past measurements of a pregnancy can be incorporated so that the
reference values can be individualized.
As is generally known, the BayesianMCMC estimation procedure allows us to
easily change some of model components, which is a great advantage over some
other computational approaches. Herewe replaced the usual normally distributed
error term by t-distributed errors. In addition, we have examined the effect that
covariates may have on early embryonic growth. Currently, we are also looking if
we can use the subject specific effects in our model to predict birth outcomes. In
the Bayesian methodology the individual estimates are automatically shrunken
which is advantageous for prediction.
In theory the MSITAR model can be extended to more than three outcomes.
However from a practical point wemust admit that themodel will quickly become
too complex to fit. Still, to apply theMSITARmodel tomore than three dimensions,
the current approach might be combined with a dimension reduction technique
as in [Slaughter et al., 2009]. Furthermore, here we have analyzed the ‘normal’
pregnancies. Another approach could be to take basically all pregnancies. This
strategy might be preferred because in the early period after conception it is
sometimes hard to know whether the pregnancy will be aborted. In fact, one of
the reasons for setting up the Rotterdam Predict study is to discover abnormalities.
Such a sample will require, however, that we model the random part of the
MSITAR model more flexibly. We are currently working on these and other
extensions in a Bayesian context.
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Appendices
3. A multivariate Bayesian model for embryonic growth
Introduction
In the paper ‘A Multivariate Bayesian model for embryonic growth’ we presented
an extension of the SITAR model so that multiple outcomes could be modeled.
Here we show some details that did not fit in the main paper, but which we think
are interesting for some readers. First we give the full conditionals of the model.
In section 3.B we show how we can sample from the predictive distribution. The
last section of the supplementarymaterial we look at the distribution of the subject
specific effects and check whether they have a normal distribution.
3.A Full conditionals
We used a Bayesian approach to estimate the model parameters of the model (2)
given by the following posterior distribution:
p(α, β, σ2 , γM ,ΣMγ | y) ∝
∏
i jk
N(yi jk | γi2k + zi jk(γMi )>βk , σ2k)×∏
i
N(γMi | 0,ΣMγ )×∏
k
N(αk | 0, σ2α,0 Inp )
∏
k
N(βk | 0, σ2β,0 Iκ+2)×∏
k
IG(σ2k | ασ , βσ) IW(ΣMγ | δ,Ψ),
The notation used is explained in the main paper. Additionally we use:
β  (β>1 , . . . , β>K)> ,
σ2  (σ21 , . . . , σ2K)> , (3.1)
γM  (γM1 , . . . , γMN )>and
y  (y111 , y121 , . . . , y1ni1 , y211 , . . . , yN,nNK ,K)>.
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3.B. Sampling from the predictive distribution
The (block) full conditionals for β, α σ2k and ΣMγ are:
βk | y , . . . ∼ N(µk ,Σβk ),
where µk 
1
σ2
ΣβkZk y˜k ,
Σβk 
(
Σ−1β + Z
>
k Zk/σ2k
)−1
;
α | y , . . . ∼ N(µα ,Σα),
where µα  Σα[(X> ⊗ Σ−1Mγ)γM,vec],
Σα  [X>X ⊗ Σ−1Mγ + Inp×Kσ2α,0]−1;
σ2k | y , . . . iid∼ IG
(
ασ +
K
2 , βσ +
∑
i , j{yi jk − γi2k − B(exp(γi3k)(ti j + γi1k))}2
2
)
;
ΣMγ | y , . . . ∼ IW (δ + ni , (Ψ−1 + (γM − XA>)>(γM − XA>))−1) .
In the above expressions, µk and Σβk are the mean and the variance of the full
conditional distribution of the spline coefficients βk . The (
∑N
1 nik × (κ + 2)) matrix
Zk is the splinebasiswith as rows the zi jk at the current values of theparameters γ1k
and γ3k . Further, y˜k is defined as (y11k − γ12k , y12k − γ12k , . . . , y1n1k − γ12k , y21k −
γ22k , . . . , yNnN k − γN2k)>, µα and Σα denote the mean and variance of the full
conditionals of α. We also used the notation: X for the N × np design matrix
[x1 , x2 , . . . , xN ]> and γM,vec  [γ>M1 , . . . , γ>MK ]> for the matrix consisting of the
stacked rows of γM and the symbol ‘⊗’ for the Kronecker product.
The above full conditionals are of standard form and hence the usual samplers
can be used. However, this is not the case for the full conditional distribution of
the subject specific effects, given by:
γMi |y , . . . ∼ N3K(γMi | Axi ,Σγ) ×
∏
j,k
N(yi jk | γi2k + γi3kB(ti j + γi1k)βk , σ2k), (3.2)
where a Metropolis step is needed.
3.B Sampling from the predictive distribution
We perform cross-validation to assess the predictive ability of the models. We
split the data in five approximately equal parts. In turn one of the parts will
be the validation set and the other the training sets. For each individual in the
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validation set we want to draw samples from the predictive distribution of the last
observation in each series given the observations that were made previously and
also given the information we have obtained from the individuals in the training
set.
We denote the last observation from each combination of pregnancy and
outcome by yik ,LAST. This is the observation we want to predict. The earlier
observations for this pregnancy onwhich this predictionwill be based (in addition
to the information in the training set) are yi ,O . Here we use the subscript O to
denote that these are the Observed measurements of the new pregnancy.
We can draw samples from the predictive distribution of yik ,LAST as follows:
• Based on the data of the training set, denoted as yT , we have stored the
sampled values of all the parameters denoted as θ˜1 , . . . , θ˜NT , where NT
denotes the number of stored samples.
• For a pregnancy in the validation set, we determined the multivariate
distribution of γMi from expression (3.2) in the main paper, based on both
the sampled θ˜ parameters and the observed yi ,O . This results inNT sampled
parameters γ˜Mi ,1 , . . . , γ˜Mi ,NT . Note that yi ,O is not used to update θ. The
idea is that the observations for each pregnancy in the validation set are
only used to learn its specific effects but not to update our knowledge of the
other parameters.
• Using these subject specific effects, we now predict the values at the last
observationof eachoutcome k of eachpregnancy i (yik ,LAST) in thevalidation
sample. That is, we predict the values yik ,NEW from N(γ˜i2k + γ˜i3kB(ti jk +
γ˜i1k), σ˜2k). The predicted response is based on the sampled values θ and
γMi and results in NT sampled values y˜ik ,LAST,1 , . . . , y˜ik ,LAST,NT . We then
took the average over these samples to obtain the predicted values yˆik ,LAST.
Theprocedure outlined above is followed for all pregnancies using eachof theparts
as validation sample in turn. We calculated the RMSE for each of the outcomes as√∑Nk
i1(yik ,LAST − yˆik ,LAST)2/Nk . Here Nk are the number of pregnancies for which
we observed the kth outcome.
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3.C. Normality of the subject specific effects
3.C Check of the normality assumption of the
distribution of the subject specific effects
We have shown that there were advantages of modeling the outcomes together
instead of separately and checked the assumptions of our models by using poste-
rior predictive checks. From these checks, we saw that the fit could be improved
by changing the distribution of the residual error from a normal distribution to a
t-distribution. Because the usual posterior predictive checks focus on the residual
error we used another approach to look at the distribution of the subject specific
effects. Here, quantile-quantile plots (qq-plots) of the subject specific effects for
all models are fitted. In turn we present the qq plot of the univariate model
with normally distributed errors (Figure 3.1), the multivariate model with normal
errors (Figure 3.2), the univariate models with t-distributed errors (Figure 3.3)
and the multivariate model with t-distributed errors (Figure 3.4). The qq-plots
compare the sample quantiles of the fitted subject specific effects with the theoret-
ical quantiles of the assumed distribution. Note that we do not actually observe
the subject specific effects which reduces our ability to detect deviation from the
assumptions.
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Horizontal shift Vertical shift Stretch
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Figure 3.1: QQ-plots for the univariate SITAR models with normal distributed errors
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3.C. Normality of the subject specific effects
Horizontal shift Vertical shift Stretch
CRL
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Figure 3.2: QQ-plots for the multivariate SITAR model with normally distributed errors
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Figure 3.3: QQ-plots for the univariate SITAR models with t-distributed errors
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3.C. Normality of the subject specific effects
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Figure 3.4: QQ-plots for the multivariate SITAR model with t-distributed errors
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4. Flexible multivariate nonlinear models for bioequivalence problems
Abstract:
Modeling the concentration of a drug in the bloodstream
over time is usually done using compartment models. In phar-
macokinetic data they turn into highly nonlinear mixed-effects
models (NLMEMs) when we take the heterogeneity between
subjects into account. Fitting of NLMEMs can be difficult and
may involve complex algorithms, with convergence critically
depending on the initial values and maybe requiring data trans-
formations. In this paper, we propose a flexible alternative to the
usual parametric compartment models, inspired by the Multi-
variate SuperImposition by Translation and Rotation (MSITAR)
model but adapted to be applicable in this new field. A fully
parametric one-compartment nonlinear mixed-effects model is
considered for comparison. Wemakeuse of a Bayesian approach
and illustrate the method on a real data set where the interest
lies in contrasting the average and individual bioequivalence of
a test and reference formulation of an antihypertensive drug.
Authors: S.P. Willemsen, C.M. Russo, E.M. Lesaffre & D Leão. published in: Statistical
Modelling (2017)
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4.1 Introduction
The importance of mixed-effects models for analysing longitudinal data and re-
peated measurements is unquestionable. When the relation between covariates
and the response is nonlinear in the parameters the modeling of repeated out-
comes leads to nonlinear mixed-effects models (NLMEMs). However fitting these
models is notoriously difficult, usually involving iteratively applying numerical
integration to maximize the likelihood and requiring well-chosen initial values
and even data transformations. Challenging applications are found in the phar-
macokinetic area, where highly nonlinear models arise naturally from biological
theory about the absorption and elimination of a substance in the body. The non-
linear functions considered, however, may be too restrictive, not allowing much
flexibility. In practice, this means that if the nonlinear function is misspecified
or if the initial values for the algorithm are chosen badly, a good fit may never
be achieved. Important references on nonlinear parametric mixed effects models
are [Kuhn and Lavielle, 2005; Wu, 2004; Lindstrom and Bates, 1990]. The particular
problem of estimation is intensively discussed by Pinheiro and Bates [1995], where
different approximations to the log-likelihood are proposed.
Prior to introducing a new drug on the market the manufacturer needs to
show, among other things, that it is metabolised in the same way as an equivalent
drug that already holds a patent. An example is the proposal of a generic drug
as an alternative to a brand-name drug. To achieve this, pharmacokinetic models
are used to describe the processes of absorption, distribution and excretion of the
drug in the human body. We want to know what portion of the drug reaches
the patient’s circulation and thus is available to the organs, which is called the
bioavailability. When the bioavailability of two drug formulas is equal they are
called bioequivalent.
When a series of blood concentration measurements is available from subjects
who have taken the original and new drug formulation, pharmacokinetic models
could be used to demonstrate that the whole curves of drug concentration as
a function of time do not materially differ between the two drugs formulations.
The regulatory agencies FDA and EMEA recommend the comparison of two
bioavailability parameters: the maximum drug concentration achieved (Cmax)
and the area under the drug concentration-time curve (AUC), see Figure 4.1. To
demonstrate population bioequivalence, the ratio of the bioavailability parameters
69
4. Flexible multivariate nonlinear models for bioequivalence problems
0 2 4 6 8 10
0
50
10
0
15
0
Time (h)
S
u
bs
ta
nc
e 
co
nc
en
tra
rio
n
●
Cmax
AUC
Figure 4.1: Illustration of the Bioavailability parameters Cmax and AUC.
for the two drugs should be close to one [U. S. Food and Drug Administration, 2001;
European Agency for the Evaluation of Medicinal Products, 2001]. Specifically, FDA
and EMEA recommend to check if
0.8 ≤ Cmax ,2
Cmax ,1
≤ 1.25 and 0.8 ≤ AUC2AUC1 ≤ 1.25. (4.1)
with a high degree of certainty. In this equationwe use subscript 1 for the reference
drug and 2 for the new drug. Usually this is tested by carrying out two one-sided
t-tests for each outcome both at the 5% level, which is equivalent to the 90% CI
lying entirely within these boundaries.
Notwithstanding this recommendation, there have been attempts to use non-
linear mixed-effects compartmental models to assess bioequivalence in the strict
sense [see e.g., Chen and Huang, 2013; Fradette et al., 2005;Hu et al., 2004]. A compar-
ison between a non-compartmental analysis (NCA) and a nonlinear mixed-effects
model (NLMEM) is presented in [Dubois et al., 2010]. More recently, a stochas-
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tic approximation expectation maximization (SAEM) algorithm was proposed by
Dubois et al. [2011]. The authors also proposed aWald test to assess bioequivalence
in a strict sense.
Note that condition (4.1) only deals with average bioequivalence not with
individual bioequivalence. Hence, even when the drug formulations behave
similar on average, this does not mean that the formulations behave the same for
each individual patient. It is this individual bioequivalence that is relevant for
the ease with which patients that currently use the reference drug can switch to a
new drug formula.
In this paperwe propose amodel that is data driven rather than based on a the-
oretical biological model. Our model relies on the Multivariate SITAR (MSITAR)
model, recently proposed by [Willemsen et al., 2015] for embryonic growth data.
The MSITAR model is a multivariate extension of the SuperImposition by Trans-
lation and Rotation (SITAR) model suggested by Cole et al. [2010a]. The price of
the flexibility is that the regression parameters no longer have a pharmacokinetic
interpretation. However the MSITAR model still allows for performing tests of
bioequivalence based on credibility intervals of the bioavailability parameters
Cmax and AUC. Moreover, here the MSITAR model gives a better fit and conse-
quently a greater reliability on the bioequivalence conclusion may be obtained.
This paper unfolds as follows. Section 4.2 introduces themotivating example a
pharmacokinetic trial investigating the bioequivalence of two formulas of Losartan.
In Section 4.3 we briefly discuss the parametric nonlinear mixed-effects models
that are used for pharmacokinetic data and propose a SITAR-type model as an
alternative to analyze these nonlinear longitudinal pharmacokinetic data. Section
4.4 details some of our modeling choices, explains how we use the models to
evaluate bioequivalence and discusses theway that we have evaluated ourmodels.
Section 4.5 is dedicated to the analysis of the application and a discussion is
provided in Section 4.6.
4.2 Motivating example
A bioequivalence trial was set up to compare the pharmacokinetic profile of
a generic formulation (test drug) of Losartan, an anti-hypertensive drug, and
the original Losartan formulation (reference drug). To this end, a crossover
randomized study with 24 healthy volunteers was set up. Reference and test
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formulations of the drug were administered to each individual on different days
in a randomized order, ensuring no carry-over effect. The drug concentration was
observed at fixed time points: 0, 20min, 30min, 40min, 60min, 80min, 100min,
2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5, 5.5h, 6h, 6.5h, 7h, 8h, 9h, 10h, 14h and 24h. In
Figure 4.2 we show the pharmacokinetic profiles under both formulations for two
randomly selected individuals. The first measurement was taken when the drug
was administered and the last measurement was taken 24 hours later. We see
that all profiles start at zero from which they increase quickly to reach a peak.
From there, they gradually decrease again. Note that there are some individuals
whose concentration remains at zero for a short amount of time after the start of
the experiment. Also note that there is variation in the height of the peak and
the speed at which the concentration diminishes after the peak. In Table 4.1 the
means (SD) of the blood-serum measurements at each chosen time point under
the two drug formulations are shown.
The measurement technique involved has a detection limit of 2 ng/ml and all
values below this threshold are therefore represented as zeros.
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Figure 4.2: Measurements of Losartan concentration in 24 volunteers using two drug
formulations, with the measurements of two randomly chosen individuals highlighted.
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Table 4.1: Descriptive statistics of the pharmacokinetic Losartan data. The mean, standard
deviation and median of the two formulas at all time points are shown.
Reference drug Test drug
Time mean SD median mean SD Median
0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.33 134.71 209.15 41.25 138.15 183.67 48.05
0.50 178.28 168.21 106.30 182.72 198.96 120.47
0.66 123.42 89.22 114.94 162.34 143.16 124.80
1.00 119.83 71.02 122.09 125.84 78.69 107.22
1.33 108.83 74.35 72.94 91.95 48.14 85.58
1.66 80.84 42.41 64.83 66.69 40.78 54.98
2.00 67.43 33.33 57.85 58.69 29.46 54.62
2.50 53.07 26.41 44.13 58.71 66.13 40.27
3.00 40.30 19.76 34.90 48.10 38.13 35.92
3.50 32.16 16.36 28.26 37.70 25.35 33.39
4.00 27.32 16.22 22.27 30.77 20.71 24.85
4.50 26.78 11.77 23.92 30.78 17.01 25.36
5.00 22.42 10.93 20.95 24.46 11.90 20.70
5.50 17.12 7.95 15.35 23.54 12.24 19.19
6.00 13.43 6.20 13.16 17.67 8.54 14.55
6.50 12.90 5.70 11.07 13.14 6.62 11.57
7.00 10.71 5.67 9.02 10.45 5.52 8.77
8.00 6.78 3.70 5.53 6.83 3.69 5.93
9.00 4.87 2.56 4.64 4.65 3.25 4.29
10.00 2.92 2.64 2.73 3.06 2.71 2.95
14.00 0.40 0.93 0.00 0.38 1.04 0.00
24.00 0.00 0.00 0.00 0.00 0.00 0.00
4.3 Approaches to assess bioequivalence
In this sectionwe introduce the first order compartmentmodel, which is one of the
most used pharmacokinetic models that can assess bioequivalence as specified
in (4.1). We then briefly discuss non-compartment analysis, which is a non-
parametric alternative to determine bioequivalence. A third alternative to assess
bioequivalence is based on a multivariate extension and adaptation of the SITAR
model. The correlation among the repeated drug concentrations is taken care of
by random effects.
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First order compartment model
Theabsorptionandeliminationof a substanceby thebody isusuallymodelledwith
a compartment model. One distinguishes between single- andmulticompartment
models. In the single compartment model, the human body is represented as
a single compartment that is absorbing the drug and from which it is naturally
eliminated afterwards. When absorption and elimination occur at a constant rate
the following equation forms the basis of the first order open compartment model:
dX(t)
dt
 kaFD − keX(t) and Y(t)  X(t)/V. (4.2)
Here X(t) is the amount of drug in the blood at time t, F represents the fraction of
the drug that is absorbed), D the administered dose, ka the absorption rate, ke the
elimination rate, V the volume of distribution and Y(t) the drug concentration in
the serum. This model (plus measurement error) can be rewritten as:
Y(t)  FDka
Vka − Vke [exp(−ke t) − exp(−ka t)] + ε.
This expression is called the integrated form. Measurement error ε is introduced
because the observed concentration levels deviate from the theoretical biological
model because of e.g. measurement error. As a function of time t, the drug
concentration takes the form of a constant times the difference between two
exponential terms.
One clear advantage of this parametric model is the interpretability of its
parameters. Although neglected by some authors, the parameters should be
positive, which is achieved by working with parameters defined on a logarithm
scale: lKa  lo g(ka), lKe  lo g(ke) and lCl  lo g(Cl)  lo g(keV). The parameter
Cl is called the clearance.
Note that D and F and Cl−1 all have the same multiplicative effect on Y and
therefore cannot be estimated separately in this experiment. In the remainder
they are therefore absorbed in the parameter Cl. We now arrive at the following
equation:
Y(t)  exp(lKa + lKe − lCl) [exp(−e
lKe t) − exp(−e lKa t)]
e lKa − e lKe + ε. (4.3)
The parameters in this case are interpreted as the logarithm of the substance
absorption rate (lKa), the logarithm of the substance elimination rate (lKe) and
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the logarithm of plasma clearance (lCl) [Pinheiro and Bates, 2000]. Notice that in
this model the parameters are not fully identified. When lKa and lKe are reversed
the profile stays the same. We will assume here that lKa > lKe.
The parameters in model (4.3) usually vary between individuals. Here wewill
extend the model to incorporate the multilevel structure of the data. We assume
a lognormal distribution for ke , ka and Cl (and hence a normal distribution for
lKe, lKa and lCl) as these parameters are usually lognormally distributed in
the population. Denote by yik  (yi1k , . . . , yimi k)> the vector of mi observed
substance concentrations in the ith subject after the administration of the k-th
drug, for i  1, . . . , n and k  1, . . . , K. In the motivating example, K  2 and
k  1 for the reference drug and k  2 for the test drug. Thus the model for the
jth response of the kth drug formulation of the ith individual is given by
yi jk  exp(lKaik + lKeik − lClik)
[exp(−e lKeik ti j) − exp(−e lKaik ti j)]
e lKaik − e lKeik + i jk , (4.4)
where lKaik  lKak + γi1k , lKeik  lKek + γi2k and lClik  lClk + γi3k ; lKak , lKek
and lClk are the fixed-effects related to the k-th response; γi1k , γi2k and γi3k are the
respective random effects. The usual assumption for the vector of random effects
related to the i-th individual is to assume a normal distribution for γi where γi 
(γ>i1 , . . . , γ>iK)> and γik  (γi1k , γi2k , γi3k)> is the vector of random effects related
to the k-th response of the i-th individual for each k  1, . . . , K and i  1, . . . , n.
The residual random errors i jk ∼ N(0, σ2k) are assumed to be independent of
each other and of the random effects. Note that the dependence between the two
formulas is introduced bymodeling the stacked vector of random effects fromboth
drugs as one (possibly correlated) multivariate normally distributed parameter.
Conditional on these random effects the concentrations of the two drug formulas
are assumed to be independent.
Figure 4.3 describes the effect of including each of the random effects in a fully
parametric nonlinear mixed-effects model. We see that lCl stretches the whole
curve upwards. The greater lKe the steeper the decrease at later time points and
the lower the initial slope at the start. A higher lKa renders the initial slope steeper.
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Figure 4.3: Random effects interpretation for the compartment model.
Non-compartmental models
In the previous section we have explained pharmacokinetic compartment models
in the context of bioequivalence tests. However in practice, the bioequivalence
of drugs is usually assessed by a Non-Compartment Analysis (NCA). In this
approach the AUC is obtained by applying a quadrature rule on the observed con-
centrations and Cmax is estimated by themaximumof the observed concentrations.
This approach does not assume a particular form of parametric model and thus
fewer assumptions are required to perform NCAwhen compared to model-based
approaches. On the other hand the number of observations per subject should be
sufficiently high [see, for example, Dubois et al., 2010] because in a small sample
the estimates may be biased. NLMEMs, which are fully parametric, are often
more efficient. In this paper we are also interested in the entire evolution of the
drug concentration over time and not only in summary statistics of the profiles.
Therefore we will not pursue NCA further in the remainder of this paper.
The SITAR model
The SITAR model proposed by Cole et al. [2010b] is a versatile tool to model
non-linear functions to longitudinal data sets suggested in the context of growth
models. The SITAR approach consists of shifting and/or stretching a longitudinal
template curve in different directions, delivering flexible fitted subject-specific
profiles guided by the data variability.
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Let yi j be the response at the time ti j of individual i. The original SITAR
model is then given by the following equation:
yi j |γMi , β, σ2k ∼ N(T>i j β + γi2 , σ2k), i  1, . . . , n; j  1, . . . ,mi ,
Ti j  B(exp(γi3)[ti j + γi1]),
where Ti j is the vector representing the B-spline expansion of a time for individual
i at occasion j. The function carrying out the expansion is denoted by B, β
is the vector of spline coefficients, γi  (γi1 , γi2 , γi3)> is the vector of random-
effects, consisting of γi1 a horizontal shift, γi2 a vertical shift and γi3 a horizontal
stretch. Originally a restricted cubic spline was used, which implies that the
second derivative of the spline is zero at the outer knots and the spline is linearly
extrapolated outside these values. The parameter σ2k is the variance of the residual
error of the model. A multivariate version of the SITAR model (MSITAR) was
proposed recently byWillemsen et al. [2015].
The original SITAR model is however not entirely appropriate to model phar-
macokinetic data, therefore we will make a slight modification. In Figure 4.2, it
can be seen that some profiles are stretched out. This justifies the use of both hor-
izontal and vertical stretch random effects. As all profiles start at a concentration
of zero and asymptotically approach zero, a vertical shift does not make sense.
For these reasons we adapted the original SITAR model to our needs here. We
also adapted the restrictions of the spline to better match the pharmacokinetic
purpose, i.e. we restrict the first derivative (as well as the second) to zero at the
right outer knot and define the spline to be zero at and beyond the outer knots.
Because all curves start at zero we also restricted the horizontal shift to be negative
or zero. A negative shift stands for a delay in the absorption into the bloodstream
as is observed in some patients. We now arrive at a modified SITAR model better
suited for pharmacokinetic data:
yi j |γMi , β, σ2 ∼ N(exp(γi2)[T>i j β], σ2),
Ti j  B(exp(γi3)[ti j +min(γi1 , 0)]).
(4.5)
The adapted multivariate MSITAR model is now given by:
yi jk |γMi , βk , σ2k ∼ N(exp(γi2k)[T>i jkβk], σ2k),
Ti jk  B(exp(γi3k)[ti j +min(γi1k , 0)]),
(4.6)
where yi jk be the kth response at the time ti j of individual i i  1, . . . , n; j 
1, . . . ,mi and k  1, . . . , K. Ti jk is a matrix with bases of cubic splines for the kth
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response of the individual i at time j, βk  (βk1 , . . . , βkL)Ë is the vector of spline
coefficients related to the k-th response (here L denotes the degrees of freedom of
the spline), γik  (γ1ik , γ2ik , γ3ik)> is the vector of random-effects for individual i.
Note that, although the parameters in the MSITAR model have a clear inter-
pretation, their interpretation is no longer based on pharmacokinetic theory.
Figure 4.4 describes the effect of each of the subject-specific effects in the
adapted variant of the MSITAR model. Notice that in the one-compartment
model the function of the clearance is like the vertical stretch.
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Figure 4.4: Random effects interpretation of the horizontal stretch γ1, the vertical stretch γ2 and
the horizontal shift γ3 in the SITAR model.
The first random effect represents a horizontal shift, the second random effect
a vertical stretch, and the third random effect a horizontal stretch.
To give a visual representation of both the MSITAR and the compartmental
models we have provided the directed acyclic graphs as Appendix 1.
4.4 Modeling aspects
In this sectionwe give further details about howwe fittedmodels (4.4) and (4.6) to
the data of the Losartan study. We first discuss the priors used and general aspects
of the modeling exercise. Next, we explain how bioequivalence and particularly
individual bioequivalence is assessed. Then we show how censoring was allowed
in the model. We conclude this section by detailing the diagnostic checks that we
performed.
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Priors and estimation
A Bayesian approach was used to fit the models and to assess the bioequivalence
of the curves. The currently available Bayesian computational tools enabled us
to implement models with random effects without much difficulties. For the
parametric nonlinear mixed-effects models we have taken independent N(0,1000)
priors for the regression coefficients lKak , lKek and a gamma distribution for the
precision of random errors i.e., σ−2k ∼ Gamma(0.001, 0.001). For the variance of
the random effects we used a scaled inverse Wishart [Gelman et al., 2012]. This
means that we use γipk  bipkξik where bi  (bi11 , bi21 , . . . , bi3K)Ë has an inverse
Wishart distribution with six degrees of freedom and prior variance Ω and ξik
has a uniform distribution on [0, 100]. This scaled inverse Wishart leads to an
improved convergence relative to the more standard inverse-Wishart.
In the MSITAR model similar independent vague normal priors were taken.
For example, for the fixed-effects parameters βkl , (k  1, 2; l  1, . . . , L), we used
independent N(0, 1000) priors.
For theMSITARmodel we calculated the B-spline basis on a fine grid of values
prior to the actual sampling process. In the sampling process linear interpolation
was used to evaluate the basis for time points in-between the pre-chosen grid
values. This is faster than calculating the basis at each iteration and the error is
negligible.
Markov chain Monte Carlo (MCMC) sampling was used to estimate the pa-
rameters. The models were fitted in JAGS version 4.2 which was called from R
[Plummer, 2003b]. For both models we ran approximately 2.4 million iterations of
the sampling algorithm, a quarter of which were discarded as burn-in. The data
were thinned with a factor 300 to reduce the resulting objects to a manageable size.
Appendix 2 shows the JAGS code that was used and in Appendix 3 we provide
further details about the sampling procedures in JAGS.
Bioequivalence
To test population bioequivalence of the new formula of Losartan and the reference
drug, one could set the random effects to zero and calculate Cmax andAUC for this
‘representative’ person. Alternatively one can compare themarginalmean profiles
using a double MCMC to integrate out the random effects. That is, within each
MCMCiterationweuseMCMCintegration to averageout the randomeffects. Note
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that the marginal mean profile is not equal to the profile calculated at the mean of
the random effects (nor is the marginal median equal to the profile calculated at
the median of the random effects). In addition to comparing summary measures,
we also looked at the entire marginal mean profiles. This enabled us to locate the
difference in the curves if any.
In addition to population level bioequivalence, it is also of interest to test indi-
vidual bioequivalence, see e.g. [Schall and Luus, 1993]. Individual bioequivalence
tells us whether the behaviour of the test drug is similar to the behavior of the
reference drug within patients. This is relevant when for a particular patient who
switches from the reference drug to the new formula. In that case we wish to
know the particular value of the ratio of the bioequivalence measures between the
drug formulations that we will observe. Hence, we propose to use the following
measure: ∫
OT(yPRED)
OR(yPRED)p(yPRED |γPRED , θ)p(γPRED |θ)p(θ |y)dθ, (4.7)
where O is either the AUC or Cmax and the indexes T and R specify whether
we consider the test or the reference drug. γPRED and yPRED are the random
effects and observations for new individuals respectively. So we are sampling
from the posterior predictive distribution of our bioequivalence measures. If
narrow, this procedure indicates individual bioequivalence. However, we could
argue that there is no individual bioequivalence if the 90% credible interval based
on this distribution contains either very low or very high values. Unlike for
population bioequivalence, there are no generally accepted criteria for individual
bioequivalence.
The proposed procedure by the FDA decomposes the within-subject variance
into a between-formulation and a within-formulation part [U. S. Food and Drug
Administration, 2001]. This relates the changes in the bioavailability profile that
we observe when an individual switches to a new drug to the changes that we
would expect even when the same drug formulation is taken on another occasion.
As we do not have any replicates in this study, this method cannot be used.
Detection limit
An additional feature of the motivating data set is that the technique used to
measure the drug concentration has a detection limit of 2 ng/ml; in other words,
80
4.4. Modeling aspects
the drug concentrations are left censored at 2 ng/ml. This left censoring is the
mirror image of the right censoring that is common in survival analysis. About
15% of the observations of both treatments is below the detection limit.
It has been shown that dealing with these censored observations explicitly is
better than simply substituting zero, the detection limit, or some fraction thereof
[Helsel, 2006; LaFleur et al., 2011] studied this extra complication in detail. In a
MCMC approach the incorporation of censored observations is easily done via
data augmentation. We assume that the censored values come from the same
distribution as the other observations but every time the values are below the
detection limit a zero is observed in the response variable. In the sampling
procedure we sample the unobserved values of the response from a truncated
distribution. For the stochastic parents of the response sampling can now take
place as if it were fully observed.
One should note that censored observations are effectively omitted from the
deviance that is calculated by JAGS. Therefore, we had to calculate this ourselves
using a likelihood were the censored values appear as terms with Φ(2|µ(.), τ)
where Φ is the cumulative density function of a normal tau is the precision and µ
is the mean given by the respective models given by equation 4.4 or 4.6.
Diagnostic checks and model comparison
The different models were compared using the deviance information criterion
(DIC) [Spiegelhalter et al., 2002c] and the pseudo Bayes factor [Geisser and Eddy,
1979]. The pseudo Bayes factor is defined as:
PSBF 
∏
i , j,k CPOi jk ,MSITAR∏
i , j,k CPOi jk ,COMP
Ignoring the subscripts of the model to facilitate the notation, we defined the
CPO of observation i jk as:
CPOi jk ,M  p(yi jk |y(i jk)) 
∫
p(yi jk |θ)p(θ |y(i jk))dθ.
Here M is the model (MSITAR or COMP) and y(i jk) denotes the data set without
observation yi jk . So CPOi jk expresses how surprising yi jk is in the light of the
other observations. Large values of 1/CPOi jk indicate the presence of an outlying
observation. In, e.g., Lesaffre and Lawson [2012, chap. 10], it is shown how the
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MCMC output can be used to estimate CPO. From the definition above it is clear
that the CPOs can also be used to assess themodels for for discrepant observations
[see Geisser, 1980].
We also performed posterior predictive checks (PPCs). In a PPC the predictive
distribution of a discrepancy measure is compared with the observed discrepancy
measure. In general, this proceeds as follows. First generate S replicate data sets
yreps (s  1, . . . , S). For discrepancy measure or test statistic T(y |θ) we compare
T(yobs |θ) with T(yrep |θ) where yobs represents the observed data set and yrep is
a replicated data set. The posterior predictive p-value (PPP-value) is defined as:
Pr[T(yreps |, θ) > T(yobs |θ)|y] 
#[T(yreps |θs) > T(yobs |θs)]
S
A PPC below 0.05 or above 0.95 is usually seen as an indication of a problem of
the model fit.
Here we chose the omnibus measure suggested in [Gelman et al., 2004] given
by:
X2GM 
∑
i , j,k
[yi jk − E(yi jk |θ)]2
var(yi jk |θ) , (4.8)
where the expectation and variance are calculated over the samples from the
posterior predictive distribution.
The normality of the random effects was assessed visually, by inspecting
normal probability plots of the respective posteriormeans. In addition the Shapiro-
Wilk test was performed on the posterior mean of the random effects. In both
models the null hypothesis of normality was rejected for one of the random effects.
4.5 Application
Main results and bioequivalence
Population and individual bioequivalence of the two Losartan formulations were
analyzed with the parametric compartment and with the adaptedMSITARmodel.
In a global sense the MSITAR model may give a better fit when compared to the
compartment model. This is illustrated in Figure 4.5 where the profiles fitted for
individual 15 are shown. Marginal mean curves with credible intervals of both
models presented in Figures 4.6 and 4.7 enable the comparison of both models
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on average. Apparently, the adapted MSITAR model provides more flexible
curves than the ones obtained by the compartment model, which permits, for
instance, a better fit to the concentration peak and decay. In Table 4.2 population
bioequivalence for the Losartan formulations is computed. It is of interest to see
that on the whole the CIs of the compartment model are wider than those of the
SITAR model (with the exception of AUC for population bioequivalence). For
Cmax the upper bound of the compartment model is above the critical value of 1.25
in contrast to the MSITARmodel where we can claim population bioequivalence.
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Figure 4.5: MSITAR (solid line) and parametricmodel (dashed line) fitted to data belonging
to individual 15.
Table 4.2: Bioequivalence results for the Losartan trial
Model Criterion Mean SD 5% 50% 95%
parametric Cmax ratio 1.08 0.201 0.79 1.07 1.44
MSITAR Cmax ratio 0.96 0.096 0.81 0.95 1.12
Model Criterion Mean SD 5% 50% 95%
parametric AUC ratio 1.00 0.086 0.86 1.00 1.15
MSITAR AUC ratio 1.01 0.103 0.85 1.00 1.18
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Figure 4.6: Marginal mean profile and 95%
CI for the compartment model.
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Figure 4.7: Marginal mean profile and 95%
CI for the MSITAR model
Table 4.3: Individual bioequivalence results for the Losartan trial
Model Criterion Mean SD 5% 50% 95%
parametric Cmax ratio 1.61 7.91 0.25 1.02 4.44
MSITAR Cmax ratio 1.16 0.97 0.32 0.95 2.85
Model Criterion Mean SD 5% 50% 95%
parametric AUC ratio 1.06 0.820 0.58 1.00 1.70
MSITAR AUC ratio 1.13 0.671 0.41 0.96 2.32
In Table 4.3 we show the results for the individual bioequivalence. The
90% credible intervals are much wider for the individual bioequivalence than
those for population bioequivalence. This shows that even when the drugs are
population bioequivalent, on an individual basis one cannot be sure that switching
will never lead to problems.
TheDIC of the compartmentmodel is 9 452 and theDIC of ourMSITARmodel
is 8 359, demonstrating the much better fit of the MSITAR model. The log of the
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pseudo Bayes factor was 518 supporting this conclusion.
Diagnostic analysis
To track observations that are difficult to fit, we made use of the CPO. Results
for the compartment and MSITAR models are presented in Figures 4.8 and 4.9
respectively. Both models have some problems at time points 2 to 6, i.e. near the
peak and generally do well afterwards. They both do not fit well for individual 4
who reaches the maximum concentration for the test drug much later than the
other individuals (this is also visible from Figure 4.2). All together, there are more
deviating observations in the compartment model than the MSITAR model.
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Figure 4.8: Heatmap of the CPO for the compartment model: The CPOs are organized in
a matrix with time points on the horizontal axis and the number of the individual on the
vertical axis. Darker cells indicate high values of −lo g10(CPOi jk) hence a data point with
poor fit.
The value of the omnibus PPP-value was 0.51 for the compartment model and
0.29 for the MSITAR model. So based on this test there seems to be no problem in
either model. We could not find any evidence for non-normality of the random
effects. However with the small number of volunteers that participated in the
trial, normality tests have little power.
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Figure 4.9: Heatmap of the CPO for the MSITAR: The CPOs are organized in a matrix with time
points on the horizontal axis and the number of the individual on the vertical axis. Darker cells
indicate high values of −lo g10(CPOi jk) hence a data point with poor fit
4.6 Discussion
Abioequivalence analysis is often quite challenging because it involves fitting non-
linearmixedmodels for correlated data. In this paper, some aspects for population
and individual bioequivalencewere discussed and twomodeling approacheswere
contrasted: a parametric compartment model which has a biological foundation
and a variant of the MSITAR model. This MSITAR model which was originally
developed to model human growth had to be adapted substantially to be appli-
cable to model pharmacokinetic data. In this paper we only looked at the one
compartment model to keep the comparison simple. Of course we could have
attempted to additionally fit more complicated pharmacokinetic models but we
believe we would have quickly ran into computationally issues that way.
Using the data of the Losartan bioequivalence trial, it was shown that the
adapted MSITAR model can fit the data better than the compartment model. The
explanation lies in the flexibility of the MSITAR approach which fits both the
absorption peak and the substance elimination, whereas the restricted compart-
ment model seems to prevent the absorption-elimination curve to reach higher
concentrations when the decay is relatively fast. However, despite being more
flexible and providing a better quality fit, it is important to point that the MSITAR
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approach does not provide a biological interpretation of parameters as the para-
metric compartment model does. It has to be noted though that the compartment
model is based on an abstraction of the real world that only holds approximately.
The SITAR model is a kind of semi-parametric model in the sense that the
template is modelled by a spline. One could also imagine a fully non-parametric
model where each individual curve is described by a separate spline. Such a
model would be very flexible but it would also be hard to interpret in which way
the individual profiles differ from the ‘average’ and each other. Aswill often be the
case in practice, we do not have enough data to estimate this fully non-parametric
model. In this sense the MSITAR model forms a kind of compromise between
the flexibility of non-parametric models on the one hand and interpretability and
estimability on the other.
The Bayesian approach permits us to handle special features of the data, such
as correlated data and censoring easily. When analysing the population bioequiv-
alence, we concluded that the test formula of Losartan was bioequivalent to the
reference formula. Additionally a new way to assess individual bioequivalence
was developed based on the posterior predictive distribution of the ratio between
the bioavailability measures for new individuals. Here we saw that the credible
intervals are a lot wider than for population bioequivalence. A proper investiga-
tion of individual bioequivalence requires replicate data which was not available
here.
In this paper we concentrate on assessing bioequivalence using the summary
statistics AUC and Cmax . However because we estimate the whole curves for all
individuals, an alternative would be the following approach: First, we estimate a
model which uses the same spline for both models. We can compare this model
(using formal tests or Bayes factors) with a model using two separate splines. If
the model with a single spline is just as good as the model with separate splines
we can conclude that we have average bioequivalence. When this is the case we
can proceed to look at the individuals. When the subject-specific effects do not
differ between the models, we also have proven individual bioequivalence.
We noticed heteroskedasticity in the residuals by plotting the residuals of our
model (Included as Appendix 4) against the fitted values and against time. This
was confirmed by a dedicated PPC yielding PPP-values above 0.99 for bothmodels.
However, up to now models that express the variance as a function of time or
blood concentration failed to converge. Extensions of above models allowing for
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heteroskedasticity will be explored in a subsequent paper.
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4.A Directed Acyclic graphs
Below we show the directed acyclic graphs (DAGs) of the two models specified
above. To prevent the graphs from becoming too cluttered we have omitted a few
of the intermediate deterministic nodes. In the graphs i is the (loop) index of the
individuals, j of the time points and k of the drugs.
Compartment model
The compartment model for the jth response of the kth drug formulation of the
ith individual is given by
yi jk  exp(lKaik + lKeik − lClik)×
[exp(−e lKeik ti jk) − exp(−e lKaik ti jk)]
e lKaik − e lKeik + i jk , (4.1)
where yi jk be the kth response at the time ti jk of individual i (for each i  1, . . . , n,
j  1, . . . ,mi and k  1, . . . , K); lKaik  lKak +γi1k , lKeik  lKek +γi2k and lClik 
lClk + γi3k ; lKak , lKek and lClk are the fixed-effects related to the k-th response;
γi1k , γi2k and γi3k are the respective random effects. Here, γi  (γ>i1 , . . . , γ>iK)>
and γik  (γi1k , γi2k , γi3k)> is the vector of random effects related to the k-th
response of the i-th individual for each k  1, . . . , K and i  1, . . . , n. We model
γi  b
Ë
i ξ where bi ∼ N(0,Σb) and the elements of xi are i.i.d. and uniformly
distributed on [0, 100]. The residual random errors i jk ∼ N(0, σ2k) are assumed
to be independent of each other and of the random effects.
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Figure 4.1: Directed acyclic graph for the compartment model. Hyperparameters were
omitted.
MSITAR model
The multivariate MSITAR model is given by:
yi jk |γMi , βk , σ2k ∼ N(exp(γi2k)[T>i jkβk], σ2k),
Ti jk  B(exp(γi3k)[ti jk + min(γi1k , 0)]),
(4.2)
where yi jk be the kth response at the time ti jk of individual i. Ti jk is a matrix
with bases of cubic splines for the kth response of the individual i at time j,
βk  (βk1 , . . . , βkL)Ë is the vector of spline coefficients related to the k-th response
(here L denotes the degrees of freedom of the spline), γik  (γ1ik , γ2ik , γi3k)> is the
vector of random-effects for i  1, . . . , n; j  1, . . . ,m. We model γ  biξ with
bi ∼ N(0,Σb) and the elements of ξ are uniformly distributed between 0 and 100.
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µi jk
βkγik
b ik ξ ik
Ti jk
ti jk σ2kyi jk
Db
for i in 1 : n
for j in 1 : mi
for k in 1 : K
Figure 4.2: Directed acyclic graph for the MSITAR model. Hyperparameters were omitted.
4.B JAGS code
In this appendix we give the JAGS code of the two models that we compared.
Compartment model
The listing below details the compartment model in JAGS. We called JAGS from
R using the jagsUI library (which allows us to run several chains in parallel). As
explained in section 3.1 of the main text the gammas and phis are not identified.
We therefore define ke as the lowest of the two random effects and ka as the
highest. Note that a few of the deterministic nodes we use in the program to
not occur in the main text. They mainly function to make the program clearer
and to prevent some lines from becoming too long. Like in the main article we
use i ∈ 1 . . . n as an index of the individuals, j ∈ 1 . . .m as an index for the
measurement time and k ∈ 1 . . . K as the index of the drug. lKa1, lKe1, . . . , lCl2
were renamed to beta1[1], beta1[2], . . . , beta2[3] because JAGS does not
allow the distinction between different symbols by using different numbers of
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indices. In this JAGS code m, does not depend on the individual as the data is
balanced. Note that the number of drugs K is hard-coded as two. Also the limit
of detection is hard-coded.
Listing 4.1: Compartment model
model {
for ( i in 1 : n ) {
b [ i , 1 : 6 ] ∼ dmnorm(mu.b [ 1 : 6 ] , t au .b [ 1 : 6 , 1 : 6 ] )
for ( r in 1 : 6 ) {
gammas[ i , r ] ← b [ i , r ] ∗ x i [ r ]
}
for ( k in 1 : 2 ) {
lKe [ i , k ] ← min ( phi1 [ i , k ] , phi2 [ i , k ] )
lKa [ i , k ] ← max( phi1 [ i , k ] , phi2 [ i , k ] )
ke [ i , k ] ← exp ( lKe [ i , k ] )
ka [ i , k ] ← exp ( lKa [ i , k ] )
}
phi1 [ i , 1 ] ← beta1 [ 1 ] + gammas[ i , 1 ]
phi2 [ i , 1 ] ← beta1 [ 2 ] + gammas[ i , 2 ]
phi3 [ i , 1 ] ← beta1 [ 3 ] + gammas[ i , 3 ]
phi1 [ i , 2 ] ← beta2 [ 1 ] + gammas[ i , 4 ]
phi2 [ i , 2 ] ← beta2 [ 2 ] + gammas[ i , 5 ]
phi3 [ i , 2 ] ← beta2 [ 3 ] + gammas[ i , 6 ]
} # f o r ( i in 1 : n )
t au .b [ 1 : 6 , 1 : 6 ] ∼ dwish (6 ∗ Omega[ , ] , 6 )
for ( j in 1 :m) {
for ( i in 1 : n ) {
for ( k in 1 : 2 ) {
observed [ i , j , k ] ∼ d in t e rva l ( y [ i , j , k ] , 2 )
y [ i , j , k ] ∼ dnorm(mu[ i , j , k ] , tau [ k ] ) # da t a model : t h e l i k e l i h o o d
mu[ i , j , k ] ← exp ( lKe [ i , k]+ lKa [ i , k]−phi3 [ i , k ] ) ∗
( exp(−ke [ i , k ]∗ time [ j ])− exp(−ka [ i , k ]∗ time [ j ] ) ) /
( ka [ i , k]−ke [ i , k ] )
res [ i , j , k ] ← y [ i , j , k ] − mu[ i , j , k ]
} # f o r ( k in 1 : 2 )
} # f o r ( i in 1 : n )
} # f o r ( j in 1 :m) {
for ( k in 1 : 2 ) {
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tau [ k ] ∼ dgamma(0 .001 , 0 . 001 )
}
for (u in 1 : 3 ) {
beta1 [u ] ∼ dnorm(0 , 0 .0001 )
beta2 [u ] ∼ dnorm(0 , 0 .0001 )
}
for ( r in 1 : 6 ) {
x i [ r ] ∼ dunif ( 0 , 100)
}
}
MSITAR model model
Now we present the SITAR model. In this model Bas represents the restricted
cubic spline basis that is evaluated on a fine grid of values from R. This is done
by a modified version of the ns function from the R splines package. From
which the lines that apply the restrictions on the spline basis are replaced by the
restrictions that are detailed in the paper. This modified ns function is avail-
able from the GitHub page of the first author (https://github.com/stenw/
FlexibleBioequivalence). The interp.lin function now interpolates be-
tween those values.
Listing 4.2: SITAR model
model {
# s u b j e c t s p e c i f i c e f f e c t s
t au .b [ 1 : 6 , 1 : 6 ] ∼ dwish (6 ∗ Omega [ , ] , 6 )
for ( r in 1 : 6 ) {
x i [ r ] ∼ dunif ( 0 , 100)
}
for ( i in 1 : n ) {
b [ i , 1 : 6 ] ∼ dmnorm(mu.b [ 1 : 6 ] , t au .b [ 1 : 6 , 1 : 6 ] )
for ( r in 1 : 6 ) {
gammas[ i , r ] ← b [ i , r ] ∗ x i [ r ]
}
s h i f t 1 [ i ] ← min (gammas[ i , 5 ] , 0 )
s h i f t 2 [ i ] ← min (gammas[ i , 6 ] , 0 )
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for ( j in 1 :m) {
x [ i , j , 1 ] ← exp (gammas[ i , 1 ] ) ∗ ( time [ j ] + s h i f t 1 [ i ] )
x [ i , j , 2 ] ← exp (gammas[ i , 2 ] ) ∗ ( time [ j ] + s h i f t 2 [ i ] )
mu[ i , j , 1 ] ← exp (gammas[ i , 3 ] ) ∗
inprod ( beta1 [ 1 : L ] , B [ i , j , 1 : L , 1 ] )
mu[ i , j , 2 ] ← exp (gammas[ i , 4 ] ) ∗
inprod ( beta2 [ 1 : L ] , B [ i , j , 1 : L , 2 ] )
for ( k in 1 : 2 ) {
y [ i , j , k ] ∼ dnorm(mu[ i , j , k ] , tau [ k ] )
res [ i , j , k ] ← y [ i , j , k ] − mu[ i , j , k ]
observed [ i , j , k ] ∼ d in t e rva l ( y [ i , j , k ] , 2 )
for ( l in 1 :L ) {
B [ i , j , l , k ] ← i n t e r p . l i n ( x [ i , j , k ] , grid , Bas [ , l ] )
} # f o r l
} # f o r k
} # f o r j
} # f o r i
for ( k in 1 : 2 ) {
tau [ k ] ∼ dgamma(0 .001 , 0 . 001 )
}
for ( l in 1 :L ) {
beta1 [ l ] ∼ dnorm(0 , 0 .0001 )
beta2 [ l ] ∼ dnorm(0 , 0 .0001 )
}
}
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4.C Sampling procedures in JAGS
To obtain samples from the posterior of our models we use the program ‘Just
another Gibbs sampler’ (JAGS) by Martyn Plummer [Plummer, 2003b]. This
program can been seen as a reimplementation of WinBUGS in C++, although
there are some differences. A big advantage of BUGS-like software, is that it
makes sampling from any model relatively easy as one only needs to specify
the model and the likelihood, the rest is done by the program. JAGS will then
determine the directed acyclic graph, derive the full conditionals and find suitable
samplers. The only disadvantage of JAGS or similar software is its black-box
nature, i.e. the use is not fully aware how the sampling is done. Below we give
details what samplers JAGS has used for the different full conditionals of our
models. JAGS converts the program text to a graph of nodes storing information
about the distribution of each variable and the resations that exist between them.
This graph of nodes is traversed and for each node a suitable sampler is chosen.
The samplers chosen for the MSITAR model are as follows: For the residual
variances τ conjugate gamma samplers are used.
τk | rest iid∼ Gamma ©­«ατ + 12
∑
i
mi , βτ + 12
∑
i , j
{yi jk − µi jk}2ª®¬
where n is the number of individuals and m is the number of measurement times
so nm is the total number of observations for either drug and
µi jk  exp(bi2kξ2)Ti jkβk
is the expected value under the MSITAR model. Here orderi is the covariate that
denotes the order in which the drugs are given and ατ and βτ are the prior shape
and rate parameters for the gamma prior of the τs. For the fixed effects β conjugate
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normal samplers are used:
β | rest ∼ N(µkp , τ−1βkp)
where µkp  τ
−1
βkp τ
∑
i j
A2i jkpBi jkp ,
τβkp  τβkp +
∑
i j
B2i jkpτk ,
Ai jkp  Yi jk − exp(bi2k)
∑
l,p
βl(Ti jk)l ,
Bi jkp  exp(bi2k)βl(Ti jk)p
with (Ti jk)l the lth element of vector Ti jk and τβkp the prior precision of βkp . Ai jkp
can be thought of as the response when we have removed the effect of the other βs,
while Bi jkp is the effect that a unit increase of the coefficient has on this outcome.
For the precision of the random effects a conjugate Wishart sampler is used, i.e.
Tb | rest ∼W
(
δ + n ,Ω +
∑
i
bibËi
)
,
where δ is the prior number of degrees of freedom, I the number of individuals
and Ω the prior variance matrix.
For the random effects b, a Metropolis sampler is used. Given the other
parameters bi is sampled from a distribution proportional to:
exp(−12b
′
iT
−1
b bi)
∏
jk
g(yi jk |βk , τk , bi , ξ)
Here Tb is the precision of the bs and we use g(yi jk |βk , τkbi , ξ) for the density of
the MSITAR model conditional on the random effects, that is:√
τk
2pi exp[−
1
2 (yi jk − µi jk)2τk]
For the auxiliary parameters related to the random effect variances ξ and
the censored blood concentrations yi jk , slice samplers are used. Given all other
prameters ξ is sampled from a distribution proportional to:∏
i jk
g(yi jk |βk , τk , bi , ξ),
97
4. Flexible multivariate nonlinear models for bioequivalence problems
Finally given the other parameters we can sample the elements of yi jk that are
censored from:
τkφ(τk(yi jk − µi jk))
Φ(τk(2 − µi jk))
where φ(x) is the pdf and Φ(x) is the CDF of a standard normal.
In the parametric modelmost sampler types are identical to the corresponding
ones chosen in the MSITAR model, only for the β’s slice samplers are chosen
instead of a conjugate normal sampler as the response is not linear in the fixed
effects in this model.
Sampling now begins with an adaptive phase in which samplers that require
it, can change their behavior. For the Metropolis sampler this means that JAGS
keeps track of a running mean of the acceptance rate, giving a larger weight to
more recent iterations, and the variances of the proposal distribution are adjusted
to aim for a target acceptance rate of 0.234. For the slice samplers we similarly keep
track of a weighed average of the jumps and the step size (the tuning parameter
that controls the initial estimate of the width of the slice) is adjusted accordingly
so fewer steps will have to be taken to find the correct slice of the slice. After the
adaptive phase we continue the burn-in. When we are convinced we are sampling
from the posterior we start storing the sampled values to be used in our further
analyses.
4.D Residual plots
In this section we provide the (marginal) residuals plots of the two models. They
are defined as:
yi jk − exp(lKaik + lKeik − lClik)
[exp(−e lKeik ti jk) − exp(−e lKaik ti jk)]
e lKaik − e lKeik ,
for the compartment model and as
yi jk − (exp(γi2k)[T>i jkβk]
for the MSITAR model. The heteroskedasticity is clearly visible.
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Figure 4.3: Residual plot for the MSITAR model
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Figure 4.4: Residual plot for the compartment model
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5. Two-dimensional longitudinal expectiles
Abstract:
The tails of a distribution (theoretical or observed) can be
characterized by extreme quantiles. In growth studies quantile
curves, conditional on age, are familiar. Expectile curves are a
less well known, but powerful alternative. Expectiles generalize
the mean in the same way that quantiles are a generalization
of the median. We generalize the concept of expectiles into
two dimensions by first projecting the data on a line in certain
direction and than calculating the expectiles in the usual way. If
we connect the expectiles in several directions a circular expectile
contour arises. We can combine these circular contours with
the concept of conditional expectiles to create what we call
expectile tubes. They are a useful way to visualize how extreme
a multivariate observation is, in relation to a distribution.
Authors: S.P. Willemsen & P.H.C. Eilers
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5.1 Introduction
In the medical field growth charts are used to describe the distribution of mea-
surements (like height) of a population. A chart of a healthy population without
(known) diseases acts as a standard to which individuals are compared. It is
known that nutritional problems and diseases are often expressed through abnor-
mal growth patterns. Therefore growth charts have become a standard part of a
pediatricians toolkit[Turck et al., 2013]. Usually the references are conditional on a
covariate: leading for example trough height-for-age or weight-for-height charts.
This is done by making the reference functions of a covariate (like age). Because
usually there is no a-priory functional form known it makes sense to use B-spline
function. This smoothing can be improved upop when we use a relatively large
number of B-splines and put a penalty on the amount that neighboring spline
coefficients can differ from each other Eilers and Marx [1996].
Different types of measurements are often examined separately (as current
reference charts do not permit anything else). However it is much more infor-
mative to look at them in relation to each other. A certain weight might be seen
as to high when looked at by itself, but it might be well within the norm when
seen in relation to the hight of an individual. Univariate outliers do not have to
be multivariate outliers and vice versa. In order to detect multivariate outliers
we create multivariate reference regions. Here we will concentrate on pairs of
variables. In principle we can also study the combination of more variables but
visualization becomes problematic.
Growth charts are currently based on quantiles. As we will show, quantiles
can be computed as the solution to an optimization problemminimizing an asym-
metrically weighed sum of absolute differences [Koenker, 2005]. If we the replace
the absolute values in the optimization problem by squares we obtain expectiles,
an alternative proposed byNeweyNewey and Powell [1987]. Reference charts based
on expectiles can be used in much the same way as charts based on quantiles and
have the added advantage of being much easier to compute. Furthermore expec-
tile curves often appear much smoother and lead to less problems like crossing
curves, especially in small data sets. [Schnabel and Eilers, 2009].
The structure of this paper is as follows: We begin by formally introducing
expectiles in Section 5.2. In Section 5.4 we will use the method of Kong and
Mizera [2012] and adapt it to expectiles We then explain how we can condition
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on covariates in Section 5.3. In Section 5.5 we combine circular expectile contours
with expectile regression creation what we call ‘tubular expectile contours’ or
‘expectile tubes’. Section 5.6 applies our method on a data set of measurements of
the height and weight of Dutch boys. In Section 5.7 we conclude the manuscript
with a discussion.
5.2 Expectiles in a nutshell
The τth quantile q(τ) of a distribution is the smallest value q such that the
probability of an observation falling below it is at least τ. Given a sample y of
size n, they can be estimated by sorting the observations and then taking the
observation in position τn. They can also be obtained as the solution to the
minimization problem:
argmin
q
{(1 − τ)
∑
yi≤q
(yi − q) + τ
∑
yi>q
(yi − q)}, (5.1)
which can be solved by linear programming techniques [Koenker and D’Orey, 1987;
Portnoy and Koenker, 1997]. An advantage of this formulation is that q can be
made dependent on explanatory variables as we will show below. The population
equivalent expression for (5.1) is:
argmin
µ
{(1 − τ)
∫ q
−∞
(q − y)dF(y) + τ
∫ ∞
q
(y − q)dF(y)}
the solution is the value q for which
(1 − τ)
∫ q
−∞
(y − q)dF(y)  τ
∫ ∞
q
(y − q)dF(y) (5.2)
The τth expectile µ(τ) of a sample can be defined as the value that minimizes
the expression:
argmin
µ
{(1 − µ)
∑
yi≤µ
(yi − u))2 + τ
∑
yi>µ
(yi − µ)2},
in which the absolute differences in (5.1) are replaced by squared differences.
These sample expectiles are estimators of theoretical population expectiles given
by:
argmin
µ
{(1 − τ)
∫ µ
−∞
(µ − y)2dF(y) + τ
∫ ∞
µ
(y − µ)2dF(y)}
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Figure 5.1: Illustration of an quantile. The
curve shows the probability density func-
tion of an distribution. Hence the colored
areas are the fraction of possible outcomes
below and above q. For the τth quantile the
ratio between them is equal to τ/(1 − τ)
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Figure 5.2: Illustration of an expectile. The
curve shows the cumulative distribution
function. So on horizontal axis we have
the possible values the distribution can take
while (loosely speaking) the vertical axis
can been seen as he fraction of the popula-
tion with this value of x. Hence the colored
areas are the expected shortfall and the ex-
pected surplus. The ratio between these is
specified by τ/(1 − τ)
the solution is the value µ for which
(1 − τ)
∫ µ
−∞
(y − µ)dF(y)  τ
∫ ∞
µ
(y − µ)dF(y) (5.3)
is met. Hence, it is clear that the ratio of τ to 1 − τ determines the ratio of the
expected distance of a value to the expectile given that the observation falls below
the expectile to the expected distance conditional on being above the expectile.
An other way to think about expectiles is to see that it is a ‘fair’ bet to agree to pay
an amount τ for each unit that a realization of the distribution is above µ(τ) to
receive an amount 1 − τ for each unit that the outcome is below this boundary.
In figure 5.1 we have visually illustrated an quantiles of the distribution. The
curve is the probability distribution function f from which the data originate.
The blue part corresponds to the probability mass below the quantile while the
pink part lies above the quantile q. These areas correspond the the integrals in
(5.2). When balance is obtained in (5.2) the ratio between these areas should be
τ/(1 − τ).
In figure 5.2 we illustrate expectiles in an analogous manner. The curve here
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is the cumulative distribution function F. The blue area corresponds to the values
between F and the line that denotes the expectile (the think black line) for values of
the distribution that fall below the expectile and the pink area are values between
the expectile line and F for values that lie above of it. If a point lies further
from the expectile, its impact is larger. It can be shown that the integrals in (5.3)
corresponds to these two areas. τ controls the ratio between the blue and the pink
areas and hence specifies the expectile. Clearly, µ(0.5) is just the mean. In the
remainder of this article we are mainly working with a single expectile at a time
and will omit the dependence of the expectiles µ on τ in the notation.
Except in the case that τ  0.5, there is no closed form solution, however
we can use the least asymmetrically weighted squares (LAWS) algorithm. This
algorithm was proposed by Newey and Powell [1987] who named it Asymmetrical
Least Squares or ALS. To avoid the confusion with the desease that uses the same
abbreviation it was renamed LAWS.
When we define a weight function:
w(τ, yi) 
{
τ if yi > µ(τ)
1 − τ if yi ≤ µ(τ) (5.4)
(5.2) can now be written as:
argmin
µ
{w(τ, yi)
∑
(yi − µ))2 (5.5)
The LAWS algorithm finds the solution by iterating between finding the optimal
value of µ(τ)
µ(k) 
∑
i yiw
(k−1)
i∑
i w
(k−1)
i
(5.6)
and updating the weights wi using (5.4) substituting µ(k) for µ(τ). To start the
algorithm arbitrary starting weights w(0) are needed (say 0.5 for all observations).
Because the objective function is convex it aways converges Eilers [1987]. Moreover,
convergence is usually quick (Five to ten iterations.)
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5.3 Penalized expectile regression
It is easy to see that expectiles can be made conditional on covariates. We simply
replace the parameter µ in 5.2 with a linear predictor xiβ. Hence we arrive at:
argmin
β
n∑
i
wi(τ)(yi − x>i β)2
Where xi is the vector of covariates belonging to observation i and β the vector of
coefficients. Again it makes sense to apply smoothing. To keep things simple we
describe a situation in which we have a single continuous covariate t (say time)
and we conjecture that the quantiles of y smoothly change as t increases. We
setup the following optimization problem:
argmin
β
n∑
i
w(t)(yi − B(ti)β)2 + λt
Dβ2
where B(ti) is a function that performs a B-spline basis expansion for ti and D is
a difference matrix and λ is the penalty parameter that dictates the smoothness
of the curves.[De Boor, 2001; Eilers and Marx, 1996]. Of course it is easy to include
additional covariates that do or do not need to be smoothed [Eilers and Marx,
2002]. As an illustration of expectile regression we fitted smoothed expectile
curves related to 3 values of the asymmetry parameter and 3 values of the penalty
on the Dutch boys data. The blue, orange and red lines are respectively based
on an asymmetry parameter of 0.929, 0.982 and 0.996 . These values are chosen
because they correspond to the values of 1, 1.5 and 2 sd of a normal distribution.
The fully nonparametric method to create reference curves above can be
contrasted to the GAMLSS method by Rigby and Stasinopoulos [2005] in which
a specific parametric form is assumed the parameters of which are modeled by
spline functions.
5.4 Directional expectiles and circular expectile
contours
As motivated above, it is important to look at variables in relation to each other.
To do this we use directional expectiles, adopting a method that was proposed
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Figure 5.3: Expectile regres-
sion with asymmetry corre-
sponding to 1, 1.5 and 2 sd and
λt  0.001
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Figure 5.4: Expectile regres-
sion with asymmetry corre-
sponding to 1, 1.5 and 2 sd and
λt  1
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Figure 5.5: Expectile regres-
sion with asymmetry corre-
sponding to 1, 1.5 and 2 sd and
λt  1000
for quantiles by Kong and Mizera [2012]. Directional quantiles are closely related
to the idea of half width depth proposed by Tukey [1975]. For expectiles a similar
measure of data depth can be defined [Giorgi and McNeil, 2014].
If Y  (y1 , . . . , yn)>, yi  (yi1 , y12) is a n by 2 dimensional matrix of observa-
tions and θ is a unit vector of length 2 then the τth directional expectile in direction
θ of Y is defined as the the τth expectile of Yθ. In other words we project Y on
the line in direction θ  (cos(h), sin(h))> for some angle h, and then calculate the
expectiles in the usual way. In this manner we reduce the multivariate problem
to an univariate one. For the sake of simplicity we restrict ourselves here to a
two dimensional response. This is also motivated by the fact that we primarily
see these methods as visualization techniques and displaying data with more
dimensions becomes difficult. Of course the two variables we will examine can
havewidely different scales. Here we standardize the variables, that is we subtract
the mean and divide by the standard deviation. We now minimize:
n∑
i
wi(yiθ − µ)2
We can simultaneously look at a large number of directions. If we define a 2 by m
matrix of directions Θ  (θ1 , θ2 , . . . , θm) with θ j  (cos(h j), sin(h j))T where h j ,
j ∈ 1, 2, . . .m is a number of angles placed on a grid and m is the number of
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directions. We now define the projected data as Z  YΘ. We then arrive at:
m∑
j
n∑
i
wi j(zi j − µ j)2 (5.7)
were zi j is the element of Z corresponding to individual (row) i and direction (col-
umn) j. We propose that a reference region can be derived from these directional
expectiles; To do this we need to calculate the points where the lines defining the
expectiles cross.
If we calculate the expectiles in a large enough number of directions the
resulting contours look quite good. However, they can be improved upon by
applying smoothing. In (5.7) the different angles are essentially unconnected.
However we can apply smoothing using splines and penalties.
We will now model the expectile in direction h j as a cα 
∑K
k c jkαk , where
cik is the kth component of the circular basis expansion in direction h j and α is
a vector of coefficients . This already reduces the number of parameters. We
can further increase the smoothness by putting a penalty on the amount that the
coefficients corresponding to neighboring angles can be apart. We penalize by an
amount λh ‖Qα‖2 , where Q is a circular difference matrix. By circular splines
and bases, wemean that they wrap around the origin. A cyclic spline C basis with
degrees of freedom n on [−pi, pi] consisting of columns ci with i ∈ 1 . . . n can be
defined as ci(x)  bi(x) + bi(x + 2pi). Where bi is the ith spline function (column)
of a regular B spline basis with n degrees of freedom of degree d with n + 1 + d
knots equally spaced on [−pi, pi + 2dpin ]. This is illustrated in Figure 5.9.
For the penalty matrix we work in a similar way we first set up a regular
penalty matrix on a wider range and then ‘’wrap it around’.
By smoothing in this way, we avoid over-fitting and the resulting contours
have fewer sharp corners which we think is more realistic (See Figure 5.11). This
is especially the case when little data is available and the expectiles we look at are
more extreme. The problem now becomes:
m∑
j
n∑
i
wi j(zi j − c jα)2 − λh ‖Qα‖2 (5.8)
The constant λh specifies the amount of smoothing. When λh is large, coefficients
that are ‘close’ to each other cannot be too far apart, so the spline will be very
smooth. When it is small, the coefficients are almost independent, so the spline is
very flexible.
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Figure 5.6: Directional expectiles are de-
fined by projecting observations on a line
with a specified direction and then calculat-
ing the expectiles
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Figure 5.7: Directional expectiles are calcu-
lated for a large number of directions
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Figure 5.8: The directional expectiles define
a convex contour
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5.4. Directional expectiles and circular expectile contours
x
− pi 0 pi
Figure 5.9: Illustration of cyclic splines: To create a cyclic spline of [−pi, pi].we first define a
regular B-spline. The splines only sum to one in the middle (grey area). If the spines at the
right side of the grey area are shifted to the lift by 2pi we have created a cyclic spline basis.
1 −2 1 0 0 0 0 0 0
0 1 −2 1 0 0 0 0 0
0 0 1 −2 1 0 0 0 0
0 0 0 1 −2 1 0 0 0
0 0 0 0 1 −2 1 0 0
1 0 0 0 0 1 −2 1 0
-2 1 0 0 0 0 1 −2 1
©­­­­­­­­­­­­­­­«
ª®®®®®®®®®®®®®®®¬
Figure 5.10: Example of a cyclic penalty matrix. The entries in the last two columns wrap
around and appear on the first two columns.
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Figure 5.11: Effect of smoothing on expectile contours
In (5.8)wehave replaced the single parameter µwith a linear predictor c jα. We
now need weighed least squares to update the parameters in the LAWS algorithm.
So (5.6) is replaced by the expression
α(k)  (CTW (k−1)C + λhQTQ)−1CTW (k−1)Y,
were C is the circular spline matrix with elements ci j, W (k) is a diagonal matrix
with w(k)i j as the diagonal elements.
Without applying smoothing, there can be no more intersections of the lines
defining the expectiles then there are data points. So the contours will always
be a bit angular. However for quantile contours intersections may be behind an
other quantile frontier so (especially for extreme asymmetries) many directions
are ‘lost’.
Directional contours for quantiles can be made in much the same way as for
expectiles. However the expectile contours look much nicer 5.12.
5.5 Tubular expectile regression regression
Smoothing along different angles can be combinedwith smoothing along an other
variable (say age). For this we use multivariate smoothing [Currie et al., 2006]. To
do this we work with the tensor product of the P-splines C and B defined in 5.4
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5.5. Tubular expectile regression regression
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Figure 5.12: A quantile contour and an expectile contour compared. The asymmetry
parameter was 0.960 for the directional quantiles and 0.991 for the expectiles (both values
corresponding to 1.75 standard deviations on a normal distribution)
and 5.3 respectively. In other words we model the τth expectile in direction θ
with a covariate value of t as:
µi j(xi , θj) 
∑
k
∑
l
γi jCl(θj)Bk(ti)
We minimize: ∑
i
∑
j
wi j(zi j − µi j) + λt ‖DG‖2F + λh ‖GQ‖2F , (5.9)
using the notation ‖.‖F for the Frobenius norm. This equation is similar to (5.8)
in that we sum both over the observations and the angles. The difference is that
we now take the value of the covariate x of all observations into account and
smoothing is done in two directions simultaneously.
Minimizing (5.9) amounts to solving
[(C ⊗ B)V(B ⊗ C) + R]γ  (C ⊗ B)V vec(Z) (5.10)
for γ. Here V is the diagonal matrix of weights and R is the combined penalty
matrix R  λx Im ⊗DTD +λθCTC ⊗ In . We use array regression [Currie et al., 2006;
Eilers et al., 2006] instead of solving 5.10 directly. In this waywe prevent calculating
andmanipulating the large Kronecker products. This makes the calculations both
faster and less memory intensive.
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Figure 5.13: Height of Dutch boys with
mean (blue) and +/- 2 SD lines (red)
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Figure 5.14: Weight of Dutch boys with
mean (blue) and +/- 2 SD lines (red)
5.6 Application
We now apply our method on a subset of the data of the Fourth Dutch Growth
Study [Fredriks et al., 2000]. We have data on the height and weight of 6.848
Dutch boys. This data was originally collected to construct reference charts using
quantiles height and weight separately. Here we will analyze them together. For
our analyses we have taken the square root of age as we have more data here and
we expect that this is were the curves change fastest.
In figures 5.13 and 5.14 we show weight and height by age. We have modeled
the mean of both series by fitting P-spline functions. The absolute values of the
residuals from this fit were regression on a P spline expansion of age to obtain the
standard deviations as a function of the age for both series [Altman, 1993]. The
mean and +/- SD lines are added in dark blue and red respectively. With these
values we standardize the data points.
These standardized values are now used to estimate the 0.8 and 0.95 expectiles
in a large number of directions given the age of he boys. These values are used to
calculate the contours which are plotted in figure 5.15 and figure 5.16 for boys of
4, 10 and 16 years respectively. In 5.18 we made a three dimensional visualization
of the tubular contours.
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Figure 5.15: Circular expectiles for the Dutch boys data. The expectile contour correspond-
ing to 1 normal standard deviate is solid and that corresponding to 1.5 is dotted. The
contours for boys of age 4 are in blue, that of boys of 10 in orange and that of age 16 is in
red.
5.7 Discussion
The contribution of this manuscript to the literature is twofold: First, we have
developed a new methodology to develop multivariate reference curves based on
directional expectiles and expectile regression. Second: this methodology is then
extended to take into account a covariate. We smooth in two directions in the
direction of a covariate and in the direction of the combination of the responses
we are considering.Because we are working in a three dimensional space, data
are much sparser then they would be in two dimensions, increasing the need for
smoothing.
We imagine that these reference curves could be used by general practitioners,
pediatricians and other health care professionals involved in monitoring growth.
This would be done in more or less the same way as current reference curves but
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Figure 5.16: Circular expectiles for the Dutch boys data, plotted on the original scale. The
expectile contour corresponding to 1 normal standard deviate is solid and that correspond-
ing to 1.5 sd is dotted. The contours for boys of age 4, 10 and 16 years are plotted in blue,
orange and red respectively.
providing more insight. Because the contours are three dimensional in nature
instead of having them preprinted on paper we imagine a small application either
online or on the doctors computer in which the the age and for example weight
and height are entered. With this data and then which then displays the 3D
contours along with the observations. One can than zoom in and look at the
slice of the tube perpendicular to the age axis and see on which contour line an
observation is located.
Although we have used expectiles here quantiles can also be used. Basically
all one has to do is replace the weight function in the LAWS algorithm to
w(k+1)i 
τ − ai√
2 + (yi − xiα(k))2
Here ai is 1 when yi < xiα(k) and zero otherwise and  is some small constant
preventing the denominator to go to zero. Although it has been claimed the LAWS
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Figure 5.17: Circular expectiles for the Dutch boys data,
plotted on the normalized scale.
Figure 5.18: A 3D visualization of the tubular contours.
The 0.8 expectile contour is displayed in pink, the 0.95
contour in blue.
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5. Two-dimensional longitudinal expectiles
algorithm is problematic for quantiles this has been refuted by Schnabel and Eilers
[2013]. It is however true that convergence is much slower, i.e. more iterations of
the algorithm are needed.
In this paper we have used tubular expectile contours to make static visu-
alizations. However, when one make interactive plots a whole new range of
opportunities opens. Therefore we are currently working on an R package to
make this possible. We have visualized the three dimensional tubes using a ortho-
graphic projection. However as virtual reality technology is becoming affordable it
would also be possible to inspect them in this way. This would require additional
software to be written. We have restricted ourselves to two dimensional measure-
ments as otherwise visualization would be impossible. It would be possible to
work around this limitation when dimension reduction techniques (like PCA) are
used.
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conclusions and
discussion
General conclusions and discussion
In this thesis we have presented some innovations in growth modeling, mostly
focusing on multivariate and repeated measures. Below we present the main
findings of each chapter, followed by an overall discussion and some directions
for further research.
Main findings
InChapter 2we investigated whether it was better to model the height of children
on the original scale or on the scale of the standard deviation scores (SDS). Often
the SDS scale in growth studies is preferred as one can avoid modeling the full
complexity of the overall growth pattern. We investigated this using data on the
height of children born small for gestational age which do not show catch up
growth and were treated with growth hormone. We demonstrated that the use of
standard deviation scores (SDS) can lead to more complicated models. This leads
to a fit that might be worse than whenmodeled on the original scale. Additionally,
the model on the SDS scale sometimes showed growth patterns in which the
height decreased with age which does not make sense biologically. While in
the model on the original scale it is easy to build in the restriction that height is
non-decreasing with age, doing so on the SDS scale is much harder.
In Chapter 3 the SITAR model was generalized to multiple outcomes and
estimated using a Bayesian method. The multivariate SITAR (MSITAR) model
was used to examine the impact of several risk factors. Additionally, we used the
model to create both population as well as subject-specific multivariate reference
regions using direction quantiles applied to samples from the posterior predictive
distribution. Using cross-validation, we found that the fit of the multivariate
model improved upon that of the univariate ones. A benefit of the multivariate
model was also that the lost information due to missing values can partly be
recovered from the other outcome. Furthermore, a multivariate model allows for
the examination of the relation between the outcomes.
InChapter 4we adapted theMSITARmodel that was introduced in Chapter 3
to pharmacokinetic data. To be suitable to this new field, some features of the
model had to be changed to match the characteristics of the data. Here we
concluded that the MSITAR model provided a fit that was somewhat better than
that of a traditional compartment model. This demonstrates the usefulness of the
SITAR and MSITAR model outside the study of human growth.
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In Chapter 5we demonstrated how expectiles can be used to study a bivariate
outcome (say height and weight) that may depend on a third covariate (e.g. age).
Using the expectiles projections along several directions, circular contours can
be generated. The dependence on the direction can be smoothed using splines
and penalties. A similar smoothing technique can be employed to model the
dependence on the covariate. Combining the two we want to smooth along
two dimensions; this can be done using multivariate splines and penalties. We
conclude that the resulting tubular contours are a good and practically useful way
to appraise multivariate growth.
Overall discussion
In most sections we made use of Bayesian methodology. This approach appeals
to us based for its own sake. But it also allowed us to incorporate features like
censoring or correlated data in an much easier way than what is possible using
other methods.
Another theme that returns inmost chapters of this thesis is that ofmultivariate
modeling.
Topics for further research
One limitation of our models is that they might be difficult to apply in practice
because there is no standard software. This could be easily remedied by creating
an R package.
Certain features of the data were not fully incorporated in the models. For
example, when modeling the height of children we observed serial correlation in
the errors. This can be partly modelled. In the MSITAR model we assumed that
the residual errors were uncorrelated. This is probably not realistic. Finally in the
application of the MSITAR to pharmacokinetic data there was heteroskedasticity
that we have not further attempted to model.
The SITARmodel assumes that there is a single template function that applies
to everybody. This of course might not be the case. To accommodate different
templates in the population a mixture model is needed. An other extension to
the MSITAR model is to allow any or all of the outcomes to be categorical. In the
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context of human growth one could for example think ofmodeling developmental
stages such as the Carnegie stage of embryonic development or the Tanner stage of
the development of sex characteristics alongside other contentious measurements.
Using Bayesian methods, inclusion of these additional features in our models
is very easy however estimating the models may become very hard as will be
discussed below.
In many chapters we used Gibbs sampling to estimate our models. This
technique has many advantages but might also be quite slow. In complicated
models, with high autocorrelations, very large sample sizes are needed. Especially
when combined with other computer intensive methods like cross validation, the
running time becomes prohibitive. For this reason other techniques should be
investigated that could reduce sampling time. Perhaps the Hamiltionian MCMC
technique, implemented in STAN, could be at least a partial solution.
Another issue is the convergence of the models. When we implemented
additional features in our models we noticed that they became very sensitive to
the starting values or showed bad mixing of the chains. Here also research in new
numerical techniques is warranted, perhaps some kind of stochastic annealing
could be used.
In this thesis we have stressed thatmultiple outcomes should be examined in a
multivariate way. At the same time we have to admit that the MSITAR model and
the tubular expectiles only allow for a limited number of outcomes before they
break down. New methods involving dimension reduction are needed when we
want to model even higher numbers of outcomes. One direction might be offered
by looking at the literature for multi-modemodels (or tensor-based data reduction
models). In this field one also looks at multiple series of repeated measurements
and generalizes traditional dimension reduction techniques to work with these
multiple modes). Another possibility would be to try to devise a method that
first looks at pairwise combinations of different outcomes and combines this
information in a second stage [Fieuws and Verbeke, 2006].
When studying growth, we have looked at the development of some trait over
time. Often the growth velocity (i.e. the change over time) and the acceleration
of growth that are of interest. These could be derived from models based on size
but it could also be modeled directly.
InChapter 2we predicted the adult height of children using twomixedmodels.
Themodels aim to fit the whole growth curve well, but are not specifically focused
122
General conclusions and discussion
on predicting the final height. We therefore wonder if we can achieve better
prediction using other kinds of models. One option would be a kind of joint
model with one part describing childhood growth and the second part linking
the subject specific effects of childhood growth to adult height. It would be
interesting to see how these and other types of prediction models would compare
on predictive accuracy.
In Chapter 5 we estimate expectile and quantiles contours for a single value
of the asymmetry parameter at a time. It is easy to see how the method could
be extended to look at several values simultaneously. This would then involve
smoothing along three dimensions: age, angle and asymmetry. An other route
in which the work in this chapter can be extended is by looking at the methods
to estimate the expectiles and quantiles. They can be either estimated from a
parametric distribution or be fully nonparametric. It would be useful to com-
bine the flexibility of the non-parametric methods with prior knowledge on the
approximate parametric shape.
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Summary
This thesis deals with models for growth. In human growth studies we study 
various anthropological measurements and their development over time. Human 
growth is studied for various purposes: we can describe a population, make 
individual predictions, examine factors influencing development or study how 
(abnormal) growth patterns influence outcomes later in l ife. For this we need 
good models.
Chapter 1 gives a short introduction to the field of growth modeling. In also 
introduces some important concepts and models.
In Chapter 2 we model the height of children born small for gestational age 
that did not show catch-up growth and were treated with growth hormone. The 
main question of interest is whether it is better to model the data on the original 
scale or on the scale of the standard deviation scores (SDSs) as is often done in 
practice. We find that for this dataset modeling on the original scale produces 
more accurate outcomes. Moreover some of the growth curves on the SDS scale 
were downward sloping, which is biologically impossible.
In Chapter 3 the Multivariate Superimposition by Translation And Rotation 
model is introduced (MSITAR) as an extension of the SITAR model by Cole. In the 
SITAR model, there is a general, or template function for the overall growth 
pattern which is modeled by a spline. From this template the individual growth 
curves are then derived by shifting it horizontally and vertically and stretching it 
in the horizontal direction. Here several outcomes are modeled in this way where 
we allow the subject specific effects of each outcome to be correlated.
In Chapter 4 we apply the MSITAR model in an other field and demonstrate 
its use in a bioequivalence study. For this the model had to be slightly adjusted; 
we work with a vertical stretch instead of a shift and some restrictions are put on 
the spline to make sure it always begins at zero. Using this model we were able 
to study both population and individual bioequivalence. The MSITAR model 
was compared to a compartment model which is traditionally used to assess 
bioequivalence.
Chapter 5 returns to to topic of human growth. Here we discuss expectiles, 
an interesting alternative for quantiles. By projecting the data on lines in a large 
number of directions and calculating expectiles along each directions we can 
construct a circular reference contour. This contour can be smoothed by using
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splines and penalties. This smoothing can also be done when modeling the
dependence on a covariate. In this way we create tabular reference regions that
can be used to assess growth casually.
Finally Chapter 6 presents the main findings of each chapter and provides
some directions for further research.
Samenvatting
Dit proefschrift gaat over groei. In groeistudies kĳken we naar verschillende
antropologische metingen en hun ontwikkeling over de tĳd. Er zĳn verschillende
redenen waarom groei bestudeerd wordt: het beschrĳven van een populatie, het
maken van individuele voorspellingen van groeiuitkomsten, het onderzoeken van
factoren die een effect hebben op de groei of bestuderen hoe groei uitkomsten die
zich later voordoen beïnvloedt. Hiervoor zĳn goede groeimodellen nodig.
In Hoofstuk 1 geven we een algemene inleiding en we bespreken de context
van dit proefschrift en enkele basisbegrippen die nodig zĳn om de vervolghoofd-
stukken te begrĳpen.
In Hoofstuk 2 modelleren we de lengte van kinderen die te klein zĳn in
verhouding met de zwangerschapsduur (Small for Gestational Age of SGA) die
geen inhaalgroei laten zien en die behandeld worden met groeihormoon. We
willen onderzoeken of het beter is om eenmodel te schatten op de oorspronkelĳke
schaal of dt het beter is om de data eerst te converteren naar de standaard deviatie
score (SDS) zoals in de praktĳk vaak wordt gedaan. We zien als we data van een
trial heranalyseren dat het model op de oorspronkelĳke schaal betere schattingen
geeft. Sommige groeicurven vertonen bovendien een dalend verloop hetgeen
biologisch gezien onmogelĳk is.
InHoofdstuk 3 introduceren we hetMultivariate SITARmodel als een uitbrei-
ding op het SITAR model van Cole. In dit model, wordt een sjabloon of algemene
groeicurve met behulp van een spline gemodelleerd. Van dit sjabloon kunnen
we dan de individuele groeicurven afleiden door het horizontaal en verticaal te
verschuiven en door het uit te rekken. Hier worden verschillende groeiuitkom-
sten tegelĳkertĳd gemodelleerd waarbĳ we aannemen dat de subject specifieke
parameters gecorreleerd kunnen zĳn.
In Hoofdstuk 4 gebruiken we het MSITAR model in een ander toepassings-
gebied namelĳk in een bioequivalentiestudie. We moesten het hier wel iets voor
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veranderen; we werken hier met een verticale uitrekking in plaats ver een ver-
schuiving en we plaatsen restricties op de spline om er zeker van te zĳn dat
iedereen begint zonder een meetbare concentratie van het medicĳn in het bloed.
Gebruikmakend van het model onderzoeken we zowel de bioequivalentie op het
niveau van de populatie al individuele bioequivalentie. Het MSITAR wordt ver-
geleken met een compartment model een model dat normaal gebruikt wordt om
bioequivalentie te onderzoeken.
Hoofdstuk 5 gaat weer over menselĳke groei. We introduceren expectielen,
een interessant alternatief voor kwantielen. Door de data te projecteren op lĳnen
in een groot aantal richtingen en dan in elke richting een expectiel te berekenen
creëren we een circulair expectiel contour. We kunnen deze contouren ‘gladder’
maken door het toepassen van splines. Hetzelfde kunnen we doen wanneer we
de contouren ook afhankelĳk maken van een andere variabele. Op deze manier
worden buisvormige contouren afgeleid die gebruikt kunnen worden om groei te
visualiseren en te beoordelen.
InHoofdstuk 6 geven we de conclusies van de afzonderlĳke hoofdstukken en
doen we aanbevelingen voor verder onderzoek.
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